entity1,entity2,sentence,is_sentence_valid,doc_id,doc_title,doc_url,doc_source,date_published,entity1_input,entity2_input,sentence_entity,vec,old_sentence
loxo_101,trk,"Given LOXO-101's specificity, we do not anticipate clinical activity in patients whose tumors are not driven by TRK.",True,109156007,"Loxo Oncology, Inc. | DRS | 2014-05-14",https://www.sec.gov/Archives/edgar/data/0001581720/0000912057-14-000164.txt,secgov,1400025600.0,LOXO-101,TRK,"Given @entitya$ 's specificity, we do not anticipate clinical activity in patients whose tumors are not driven by @entityb$ .","[-0.0452777  -0.29227418  0.48532608 ...  0.03142615  0.20318437
 -0.45489305]",57
trifluoperazine,tfp,"levels, as determined by FACS, in A549 cells with shRNA targeting luciferase or rps19 and treated with A-3 or trifluoperazine (TFP).",True,76063222,CALCIUM CHANNEL BLOCKERS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES,https://data.epo.org/publication-server/rest/v1.2/patents/EP3461482NWA1/document.html,epo,1554242400.0,trifluoperazine,TFP,"levels, as determined by FACS, in A549 cells with shRNA targeting luciferase or rps19 and treated with A-3 or @entitya$ ( @entityb$ ).","[-0.29251337 -0.79863536  0.2930191  ...  0.53275913  0.04744587
  0.5979901 ]",57
minocycline,angiostatin,"Examples of chemotherapeutic and biotherapeutic agents include, but are not limited to, an angiogenesis inhibitor, such ashydroxy angiostatin K1-3, DL-α-Difluoromethyl-ornithine, endostatin, fumagillin, genistein, minocycline, staurosporine, and thalidomide; a DNA intercaltor/cross-linker, such as Bleomycin, Carboplatin, Carmustine, Chlorambucil, Cyclophosphamide, cis-Diammineplatinum(II) dichloride (Cisplatin), Melphalan,",True,113390483,Molecular biomarkers for cancer immunotherapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10975442&OS=10975442&RS=10975442,patent_grant,1618272000.0,Minocycline,Angiostatin,"Examples of chemotherapeutic and biotherapeutic agents include, but are not limited to, an angiogenesis inhibitor, such ashydroxy @entityb$ K1-3, DL-α-Difluoromethyl-ornithine, endostatin, fumagillin, genistein, @entitya$ , staurosporine, and thalidomide; a DNA intercaltor/cross-linker, such as Bleomycin, Carboplatin, Carmustine, Chlorambucil, Cyclophosphamide, cis-Diammineplatinum(II) dichloride (Cisplatin), Melphalan,","[ 0.40267813 -0.3904308   0.31573525 ...  0.22425722  0.07345573
  0.6024774 ]",57
3m_052,tlr7,"TLR7 may be activated by imidazoquinolines, such as imiquimod, resiquimod and derivatives imiquimod or resiquimod (e.g. 3M-052).",True,21011604,Formulation of a peptide vaccine,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10702598&OS=10702598&RS=10702598,patent_grant,1594080000.0,3M-052,TLR7," @entityb$ may be activated by imidazoquinolines, such as imiquimod, resiquimod and derivatives imiquimod or resiquimod (e.g. @entitya$ ).","[-0.84829396 -0.12671363 -0.4529717  ...  0.29081276 -0.69751847
  0.31077197]",25
ly3009120,braf,"In some embodiments, the cells are simultaneously exposed to a MAPK pathway inhibitor (e.g., a BRAF inhibitor (e.g., vemurafenib, LY3009120, Dabrafenib, LGX818) (e.g., a MEK inhibitor (e.g., CH5126766/RO5126766, trametinib, MEK162, PDO325901) (e.g., an ERK inhibitor (e.g., SCH772984)).",True,32326952,SMALL MOLECULE DUAL INHIBITORS OF EGFR/PI3K AND USES THEREOF,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200078360%22.PGNR.&OS=DN/20200078360&RS=DN/20200078360,patent_filed,1583971200.0,LY3009120,BRaf,"In some embodiments, the cells are simultaneously exposed to a MAPK pathway inhibitor (e.g., a @entityb$ inhibitor (e.g., vemurafenib, @entitya$ , Dabrafenib, LGX818) (e.g., a MEK inhibitor (e.g., CH5126766/RO5126766, trametinib, MEK162, PDO325901) (e.g., an ERK inhibitor (e.g., SCH772984)).","[-0.68020064 -0.3708788  -0.41750538 ...  0.5621069  -0.24142417
  0.9792942 ]",25
betahistine,h1,"Betahistine Betahistine chemically is 2-[2-(methylamino) ethyl]pyridine, and is represented by the formula: Betahistine is a histamine H1 receptor agonist and histamine H3 antagonist that crosses the blood-brain barrier and",True,6925910,TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220100204205%22.PGNR.&OS=DN/20100204205&RS=DN/20100204205,patent_filed,1281571200.0,betahistine,H 1," @entitya$ @entitya$ chemically is 2-[2-(methylamino) ethyl]pyridine, and is represented by the formula: @entitya$ is a histamine @entityb$ receptor agonist and histamine H3 antagonist that crosses the blood-brain barrier and","[-0.8445629   0.23404564 -0.09685634 ...  0.4442642  -0.87194157
  0.34930846]",4
akn-028,flt3,"embodiments, the subject is administered a CAR-expressing cell described herein in combination a FLT3 inhibitor, e.g., sorafenib (Bayer), midostaurin (Novartis), quizartinib (Daiichi Sankyo), crenolanib (Arog Pharmaceuticals), PLX3397 (Daiichi Sankyo), AKN-028 (Akinion Pharmaceuticals), or ASP2215 (Astellas).",True,93854989,THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200085869%22.PGNR.&OS=DN/20200085869&RS=DN/20200085869,patent_filed,1584576000.0,AKN-028,FLT3,"embodiments, the subject is administered a CAR-expressing cell described herein in combination a @entityb$ inhibitor, e.g., sorafenib (Bayer), midostaurin (Novartis), quizartinib (Daiichi Sankyo), crenolanib (Arog Pharmaceuticals), PLX3397 (Daiichi Sankyo), @entitya$ (Akinion Pharmaceuticals), or ASP2215 (Astellas).","[-0.33457318 -0.06539252 -0.29488716 ...  0.1930665  -0.3846014
  0.9418511 ]",4
ly3009120,braf,"in dog at 10 mg/kg, po administered as API capsule Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.",True,88262000,"Half life in dog at 10 mg/kg, po administered as API capsule",https://pubchem.ncbi.nlm.nih.gov/bioassay/1226931,bioassay,,LY3009120,BRaf,"in dog at 10 mg/kg, po administered as API capsule Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea ( @entitya$ ) as a pan-RAF inhibitor with minimal paradoxical activation and activity against @entityb$ or RAS mutant tumor cells.","[ 0.6128464  -0.18771939  0.39059725 ...  0.12139404 -0.31055903
  0.21455294]",4
loxo_101,trk,"<i>YWHAE-NTRK</i>3 expression in mouse embryonic mesenchymal cells (eMCs) induced spindle cell sarcoma, and the tumor was sensitive to the TRK inhibitor LOXO-101 both in vitro and in vivo.",True,61725311,Identification of Novel Fusion Genes in Bone and Soft Tissue Sarcoma and Their Implication in the Generation of a Mouse Model,https://doaj.org/article/173d44524adb452d87dd5418422b2dc1,doaj,1597881809.0,LOXO-101,TRK,"<i>YWHAE-NTRK</i>3 expression in mouse embryonic mesenchymal cells (eMCs) induced spindle cell sarcoma, and the tumor was sensitive to the @entityb$ inhibitor @entitya$ both in vitro and in vivo.","[ 0.3014223  -0.57032526 -0.37216252 ...  0.23177442  0.1657516
  1.1359645 ]",12
trifluoperazine,tfp,"The effect of the calmodulin inhibitor trifluoperazine (TFP) on Na, Ca and acetylcholine-induced (ACh) currents as well as on capacitance increments was investigated.",True,66973142,Trifluoperazine reduces inward ionic currents and secretion by separate mechanisms in bovine chromaffin cells.,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1193321/,pmc,460166400.0,trifluoperazine,TFP,"The effect of the calmodulin inhibitor @entitya$ ( @entityb$ ) on Na, Ca and acetylcholine-induced (ACh) currents as well as on capacitance increments was investigated.","[-0.51066226  0.1726917  -0.18927947 ...  0.4514172  -1.1138375
  0.6143733 ]",12
conatumumab,dr4,"Activators of death receptor pathway include TRAIL, antibodies or other agents that target TRAIL or death receptors (e.g., DR4 and DR5) such as Apomab, conatumumab, ETR2-ST01, GDC0145 (lexatumumab).",True,47573249,APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200345717%22.PGNR.&OS=DN/20200345717&RS=DN/20200345717,patent_filed,1604534400.0,conatumumab,DR4,"Activators of death receptor pathway include TRAIL, antibodies or other agents that target TRAIL or death receptors (e.g., @entityb$ and DR5) such as Apomab, @entitya$ , ETR2-ST01, GDC0145 (lexatumumab).","[-0.14202654 -0.2041919  -0.13185593 ...  0.21025394  0.1596445
  0.5774808 ]",12
ly3009120,braf,"regression at 40 mg/kg, po bid administered for 15 days Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.",True,24481867,"Antitumor activity against human HCT116 cells expressing KRAS mutant xenografted in athymic nu/nu mouse assessed as tumor regression at 40 mg/kg, po bid administered for 15 days",https://pubchem.ncbi.nlm.nih.gov/bioassay/1226917,bioassay,,LY3009120,BRaf,"regression at 40 mg/kg, po bid administered for 15 days Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea ( @entitya$ ) as a pan-RAF inhibitor with minimal paradoxical activation and activity against @entityb$ or RAS mutant tumor cells.","[ 0.601335    0.0377707   1.075074   ...  0.11250949 -0.28353855
  0.3603716 ]",12
trifluoperazine,tfp,"the action of CaM has been to use membrane-permeant pharmacological antagonists such as calmidazolium, W-7 [ N -(6-aminohexyl)-5-chloro-1-naphthalenesulphonamide] and TFP (trifluoperazine).",True,112113514,Calmidazolium and arachidonate activate a calcium entry pathway that is distinct from store-operated calcium influx in HeLa cells,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1133905/,pmc,1090886400.0,trifluoperazine,TFP,"the action of CaM has been to use membrane-permeant pharmacological antagonists such as calmidazolium, W-7 [ N -(6-aminohexyl)-5-chloro-1-naphthalenesulphonamide] and @entityb$ ( @entitya$ ).","[-0.4255197  -0.38316667  0.176058   ...  0.3394361  -0.83532786
  0.5859631 ]",44
digoxin,ace,"METRICS Age range Measurement Source(s) HEDIS applies to Cardiovascular ≥ 18 years Annual monitoring for patients on persistent medications (ACE/ARBs, diuretics, digoxin) ORDER a lab panel containing serum potassium and creatinine (e.g., BMP or CMP) annually for patients on ACE/ARBs and/or diuretics.",True,75278279,Preparing for Value-Based Payment: Five Essential Skills for Success,https://www.aafp.org/fpm/2017/0500/p25.html,aafp,1496268000.0,digoxin,ACE,"METRICS Age range Measurement Source(s) HEDIS applies to Cardiovascular ≥ 18 years Annual monitoring for patients on persistent medications ( @entityb$ /ARBs, diuretics, @entitya$ ) ORDER a lab panel containing serum potassium and creatinine (e.g., BMP or CMP) annually for patients on @entityb$ /ARBs and/or diuretics.","[-0.31418514  0.2822033  -0.36110198 ... -0.10550755 -0.14934577
  0.5687922 ]",44
digoxin,ace,"The various types of drugs include ACE inhibitors, Antiarrhythmic, Angiotensin II receptor blockers, Calcium Channel blockers, Digoxin, Diuretics, Nitrates, etc.",True,67298439,Herbo-mineral formulation for the treatment of cardio vascular diseases and method of preparation thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10653741&OS=10653741&RS=10653741,patent_grant,1589846400.0,digoxin,ACE,"The various types of drugs include @entityb$ inhibitors, Antiarrhythmic, Angiotensin II receptor blockers, Calcium Channel blockers, @entitya$ , Diuretics, Nitrates, etc.","[-0.5264835  -0.20289658 -0.7001739  ...  0.39525363 -0.3567245
 -0.07651273]",44
trifluoperazine,tfp,Trifluoperazine (TFP) is an FDA-approved antipsychotic drug for schizophrenia.,True,16628280,"Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R.",https://www.ncbi.nlm.nih.gov/pubmed/28062709,pubmed,1506729600.0,trifluoperazine,TFP, @entitya$ ( @entityb$ ) is an FDA-approved antipsychotic drug for schizophrenia.,"[-0.46024734 -0.44465694 -0.75263214 ...  1.2033072  -0.21448068
 -0.22618976]",44
loxo_101,trk,"Upon administration, larotrectinib (NTRK1/2/3 inhibitor, LOXO-101) binds to Trk (tropomyosin receptor kinase), causing the prevention of the neurotrophin-Trk interaction and Trk activation, and consequently resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors overexpressing Trk [ 16",True,52865957,Perspective Insight into Future Potential Fusion Gene Transcript Biomarker Candidates in Breast Cancer,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855724/,pmc,1517961600.0,LOXO-101,TRK,"Upon administration, larotrectinib (NTRK1/2/3 inhibitor, @entitya$ ) binds to @entityb$ (tropomyosin receptor kinase), causing the prevention of the neurotrophin-Trk interaction and @entityb$ activation, and consequently resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors overexpressing @entityb$ [ 16","[-0.06304859  0.02719302 -0.07493204 ...  0.2936914  -0.8186755
  0.8140773 ]",16
trifluoperazine,tfp,"There was little or no difference in the levels of serum glucose between the mice injected with calmodulin antagonist (trifluoperazine, TFP) plus endotoxin and those given endotoxin alone.",True,11530475,Calcium behavior in endotoxin-poisoned mice: especially calcium accumulation in mitochondria.,https://www.ncbi.nlm.nih.gov/pubmed/6381970,pubmed,454716000.0,trifluoperazine,TFP,"There was little or no difference in the levels of serum glucose between the mice injected with calmodulin antagonist ( @entitya$ , @entityb$ ) plus endotoxin and those given endotoxin alone.","[ 0.1990364  -0.13241325  0.03018958 ...  0.6103773  -0.5598252
  0.60191315]",16
oxaliplatin,oct2,"In another retrospective study, high expressions of OCT2 and OAT2 were identified in 60 and 36% of the cancer specimen of 90 patients with metastatic colorectal cancer treated with the combination 5-FU/leucovorin/oxaliplatin (FOLFOX).",True,81101387,"Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy—Modulators of Cellular Entry or Pharmacokinetics?",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464370/,pmc,1597190400.0,oxaliplatin,OCT2,"In another retrospective study, high expressions of @entityb$ and OAT2 were identified in 60 and 36% of the cancer specimen of 90 patients with metastatic colorectal cancer treated with the combination 5-FU/leucovorin/ @entitya$ (FOLFOX).","[ 0.05680796 -0.24264786 -0.15358727 ... -0.04339149  0.1028807
  0.5553327 ]",16
digoxin,ace,"The patient was started on intravenous furosemide, orally loaded with digoxin and angiotensin‐converting enzyme (ACE) inhibitors, along with intravenous heparin.",True,92872246,"Hyperthyroidism: a ""curable"" cause of congestive heart failure--three case reports and a review of the literature.",https://www.ncbi.nlm.nih.gov/pubmed/12556677,pubmed,1054245600.0,digoxin,ACE,"The patient was started on intravenous furosemide, orally loaded with @entitya$ and angiotensin‐converting enzyme ( @entityb$ ) inhibitors, along with intravenous heparin.","[-0.18575905  0.33423653  0.11548633 ... -0.13256238 -0.8238769
  0.6441722 ]",40
digoxin,ace,"Therefore, it is recommended that potentially nephrotoxic and renally excreted drugs (ACE inhibitors, angiotensin‐receptor blockers, aldosterone inhibitors, renin inhibitors, diuretics, NSAIDs, metformin, lithium, digoxin) should be discontinued at least temporarily during acute illness, for example serious infection, vomiting,",True,102463695,How to assess kidney function in outpatient clinics.,https://www.ncbi.nlm.nih.gov/pubmed/25521214,pubmed,1425078000.0,digoxin,ACE,"Therefore, it is recommended that potentially nephrotoxic and renally excreted drugs ( @entityb$ inhibitors, angiotensin‐receptor blockers, aldosterone inhibitors, renin inhibitors, diuretics, NSAIDs, metformin, lithium, @entitya$ ) should be discontinued at least temporarily during acute illness, for example serious infection, vomiting,","[-0.46405867 -0.06156826 -0.11530364 ...  0.5040765  -0.8957052
 -0.13590464]",40
loxo_101,trk,"In fact, treatment with the TRK inhibitor LOXO-101 (larotrectinib) resulted in promising responses by STS patients with TRK fusion [ 101 , 102 ].",True,108165349,Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877600/,pmc,1520208000.0,LOXO-101,TRK,"In fact, treatment with the @entityb$ inhibitor @entitya$ (larotrectinib) resulted in promising responses by STS patients with @entityb$ fusion [ 101 , 102 ].","[-0.30906582 -0.7627612   0.0132547  ... -0.15397729  0.4463793
  0.3989065 ]",0
loxo_101,trk,"For example, for LOXO-101, we are working with collaborators to develop an appropriate companion diagnostic to identify patients with tumors that harbor TRK fusions.",True,69079948,"Loxo Oncology, Inc. | 10-Q | 2016-08-03",https://www.sec.gov/Archives/edgar/data/0001581720/0001104659-16-136570.txt,secgov,1470182400.0,LOXO-101,TRK,"For example, for @entitya$ , we are working with collaborators to develop an appropriate companion diagnostic to identify patients with tumors that harbor @entityb$ fusions.","[-0.44838327 -1.5280049  -0.51375175 ...  0.20031378  0.7775524
  0.7381705 ]",20
loxo_101,trk,"clinical pipeline to include LOXO-292, our highly selective RET inhibitor, and LOXO-195, our next-generation TRK inhibitor intended to address acquired resistance. Recent Highlights · Larotrectinib (LOXO-101) Regulatory Update and Completion of Clinical Trial Enrollment for NDA Primary Efficacy Analysis:",True,10941105,"Loxo Oncology, Inc. | 8-K | 2017-03-07",https://www.sec.gov/Archives/edgar/data/0001581720/0001104659-17-014570.txt,secgov,1488844800.0,LOXO-101,TRK,"clinical pipeline to include LOXO-292, our highly selective RET inhibitor, and LOXO-195, our next-generation @entityb$ inhibitor intended to address acquired resistance. Recent Highlights · Larotrectinib ( @entitya$ ) Regulatory Update and Completion of Clinical Trial Enrollment for NDA Primary Efficacy Analysis:","[-0.4866363   0.18157166 -0.6830633  ...  0.5501926  -0.35961366
  1.1387343 ]",20
tesamorelin,growth hormone releasing factor,"axis drugs investigated for the treatment of HIV‐associated lipodystrophy include recombinant growth hormone (GH), growth hormone releasing hormone (GHRH), tesamorelin, also known as growth hormone releasing factor (GHRF), and insulin‐like growth factor‐1 (IGF‐1).",True,17733900,Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.,https://www.ncbi.nlm.nih.gov/pubmed/21265979,pubmed,1317333600.0,Tesamorelin,Growth Hormone-Releasing Factor,"axis drugs investigated for the treatment of HIV‐associated lipodystrophy include recombinant growth hormone (GH), growth hormone releasing hormone (GHRH), @entitya$ , also known as @entityb$ (GHRF), and insulin‐like growth factor‐1 (IGF‐1).","[ 0.51647085 -0.23334605 -0.6045538  ...  0.483656    0.32971674
  0.7208579 ]",20
trifluoperazine,tfp,"The calmodulin (CaM) inhibitor trifluoperazine (TFP) can produce analgesia when given intrathecally to rats; however, the mechanism is not known.",True,37526266,Inhibition of Nav1.7 and Nav1.4 sodium channels by trifluoperazine involves the local anesthetic receptor.,https://www.ncbi.nlm.nih.gov/pubmed/16807347,pubmed,1162162800.0,trifluoperazine,TFP,"The calmodulin (CaM) inhibitor @entitya$ ( @entityb$ ) can produce analgesia when given intrathecally to rats; however, the mechanism is not known.","[ 0.35089415 -0.3495557  -0.14303328 ...  0.3559368  -0.8019097
  0.42232308]",7
digoxin,ace,"is selected from the group consisting of an anti-inflammatory agent, an immunosuppressive agent, an anti-diabetic agent, digoxin, a vasodilator, an angiotensin II converting enzyme (ACE) inhibitors, an angiotensin II receptor blockers (ARB), a calcium channel blocker, an isosorbide dinitrate, a hydralazine,",True,74088534,Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10344071&OS=10344071&RS=10344071,patent_grant,1562630400.0,digoxin,ACE,"is selected from the group consisting of an anti-inflammatory agent, an immunosuppressive agent, an anti-diabetic agent, @entitya$ , a vasodilator, an angiotensin II converting enzyme ( @entityb$ ) inhibitors, an angiotensin II receptor blockers (ARB), a calcium channel blocker, an isosorbide dinitrate, a hydralazine,","[-0.90675056 -0.1195827  -0.16987655 ...  0.5688513  -0.76924366
  0.14706758]",30
digoxin,ace,"the art and include, but are not limited to the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta blockers, diuretics, aldosterone antagonists, digoxin (Lanoxin), blood thinning medications, biventricular pacemakers, implantable cardioverter-defibrillators (ICDs), heart pumps (left ventricular assist devices,",True,1276156,Structural mutations in titin cause dilated cardiomyopathy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=09476097&OS=09476097&RS=09476097,patent_grant,1477353600.0,digoxin,ACE,"the art and include, but are not limited to the use of angiotensin-converting enzyme ( @entityb$ ) inhibitors, angiotensin II receptor blockers, beta blockers, diuretics, aldosterone antagonists, @entitya$ (Lanoxin), blood thinning medications, biventricular pacemakers, implantable cardioverter-defibrillators (ICDs), heart pumps (left ventricular assist devices,","[-0.2725047   0.20415993 -0.29688436 ...  0.43259045 -0.14163566
 -0.09581061]",30
oxaliplatin,oct2,"Previous reports have demonstrated that the organic cation transporter 2 (OCT2, encoded by SLC22A2 ) mediates the intracellular accumulation of both cisplatin and oxaliplatin in mice, rats, and humans ( 7 – 10 ), and several other cationic-type",True,106502239,Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456253/,pmc,1595808000.0,oxaliplatin,OCT2,"Previous reports have demonstrated that the organic cation transporter 2 ( @entityb$ , encoded by SLC22A2 ) mediates the intracellular accumulation of both cisplatin and @entitya$ in mice, rats, and humans ( 7 – 10 ), and several other cationic-type","[-0.06083235 -0.5607617  -0.47384173 ... -0.09450112 -0.10000736
  0.8064386 ]",27
digoxin,ace,"psychological disorder preventing patient education and follow -up Optimize HF therapy (including use and dose of ACE inhibitors or alternatives, avoiding digoxin toxicity, avoiding contraindicated drugs or drug interactions, recommending other medication changes)",True,72082284,None,https://www.hsrd.research.va.gov/publications/esp/PharmacistCare.pdf,hsrd_research_va,,digoxin,ACE,"psychological disorder preventing patient education and follow -up Optimize HF therapy (including use and dose of @entityb$ inhibitors or alternatives, avoiding @entitya$ toxicity, avoiding contraindicated drugs or drug interactions, recommending other medication changes)","[-0.06237763 -0.67318356  0.03734342 ...  0.53718716  0.23354875
 -0.05365279]",27
digoxin,ace,"Of the patients with UVH, eight with dominant RV were receiving ACE inhibitors, whereas six of those with a dominant LV were receiving ACE inhibitors and two were receiving digoxin.",True,65268708,Non-invasive assessment of ventricular force–frequency relations in the univentricular circulation by tissue Doppler echocardiography: a novel method of assessing myocardial performance in congenital heart disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1769147/,pmc,1128124800.0,digoxin,ACE,"Of the patients with UVH, eight with dominant RV were receiving @entityb$ inhibitors, whereas six of those with a dominant LV were receiving @entityb$ inhibitors and two were receiving @entitya$ .","[-0.7803212  -0.12059631 -0.6290554  ... -0.18125165  0.48685262
  0.2638829 ]",6
loxo_101,trk,"&nbsp; Milestones &nbsp; With respect to product candidates directed to TRK, including LOXO-101 and its back-up compounds, the Company could be required to pay Array up to $222&nbsp;million in milestone payments, the",True,84319888,"Loxo Oncology, Inc. | 10-Q | 2015-08-05",https://www.sec.gov/Archives/edgar/data/0001581720/0001104659-15-056524.txt,secgov,1438732800.0,LOXO-101,TRK,"&nbsp; Milestones &nbsp; With respect to product candidates directed to @entityb$ , including @entitya$ and its back-up compounds, the Company could be required to pay Array up to $222&nbsp;million in milestone payments, the","[ 0.04663933  0.8228195  -0.49389276 ... -0.19053271  0.31212738
  0.36110175]",6
digoxin,ace,"(A), or 4) 90 mg of (A) • All patients continued to receive conventional therapy which may include diuretics, digoxin, ACE inhibitors, hydralazine, nitrates, beta blockers Subject Population: • Patients hospitalized for worsening heart failure • NYHA class III-IV • Male",True,46700513,METHOD FOR TREATING SEVERE HEART FAILURE AND MEDICAMENT THEREFOR,https://data.epo.org/publication-server/rest/v1.2/patents/EP1596868NWB1/document.html,epo,1224626400.0,digoxin,ACE,"(A), or 4) 90 mg of (A) • All patients continued to receive conventional therapy which may include diuretics, @entitya$ , @entityb$ inhibitors, hydralazine, nitrates, beta blockers Subject Population: • Patients hospitalized for worsening heart failure • NYHA class III-IV • Male","[ 0.31856823  0.0312728   0.704837   ... -0.55244786  0.27041095
 -0.17491022]",6
digoxin,ace,"fibroblast growth factors, estrogen including estradiol (E2), estriol (E3) and 17-beta estradiol; drugs for heart failure, such as digoxin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors including captopril and enalopril, statins and related compounds; and macrolides such as sirolimus, everolimus or zotarolimus.",True,84821871,Coatings for Medical Devices Comprising a Therapeutic Agent and a Metallic Material,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220120323308%22.PGNR.&OS=DN/20120323308&RS=DN/20120323308,patent_filed,1355961600.0,digoxin,ACE,"fibroblast growth factors, estrogen including estradiol (E2), estriol (E3) and 17-beta estradiol; drugs for heart failure, such as @entitya$ , beta-blockers, angiotensin-converting enzyme ( @entityb$ ) inhibitors including captopril and enalopril, statins and related compounds; and macrolides such as sirolimus, everolimus or zotarolimus.","[ 0.41734946 -0.26646966 -0.28258586 ...  0.6784775  -0.03003223
  0.3553519 ]",3
minocycline,angiostatin,"herbimycin A, PNU145156E, 16K prolactin fragment, Linomide (roquinimex), thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, angiostatin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 or minocycline may be of use.",True,47529629,Dock-and-lock (DNL) vaccines for cancer therapy,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=09457072&OS=09457072&RS=09457072,patent_grant,1475539200.0,Minocycline,Angiostatin,"herbimycin A, PNU145156E, 16K prolactin fragment, Linomide (roquinimex), thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, @entityb$ , cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 or @entitya$ may be of use.","[ 0.10675044  0.13392873  0.6461929  ...  0.49573013 -0.3091
  0.34856364]",3
ly3009120,braf,"ChEMBL 1495620 Toxicity in rat assessed as hyperbilirubinemia Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.",True,12631978,Toxicity in rat assessed as hyperbilirubinemia,https://pubchem.ncbi.nlm.nih.gov/bioassay/1226888,bioassay,,LY3009120,BRaf,"ChEMBL 1495620 Toxicity in rat assessed as hyperbilirubinemia Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea ( @entitya$ ) as a pan-RAF inhibitor with minimal paradoxical activation and activity against @entityb$ or RAS mutant tumor cells.","[ 0.33333585 -0.15449981  0.26285502 ...  0.5291886  -0.38042
  0.01032197]",3
trifluoperazine,tfp,present invention have synthesized novel phenothiazine derivatives which can be used for lung cancer cells at lower concentrations than TFP (trifluoperazine) and are specific for the lung cancer cells and have found out through experiments that the novel compounds exhibit superior calcium imaging efficiency in lung cancer cells and some of them have much better efficacy than TFP (trifluoperazine).,True,14233549,Phenothiazine derivatives having CaM inhibitory activity,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10035795&OS=10035795&RS=10035795,patent_grant,1532995200.0,trifluoperazine,TFP,present invention have synthesized novel phenothiazine derivatives which can be used for lung cancer cells at lower concentrations than @entityb$ ( @entitya$ ) and are specific for the lung cancer cells and have found out through experiments that the novel compounds exhibit superior calcium imaging efficiency in lung cancer cells and some of them have much better efficacy than @entityb$ ( @entitya$ ).,"[-0.04717152 -1.1102908  -0.5044528  ...  0.12299912  0.30951473
  0.6391393 ]",3
loxo_101,trk,"A patient with a metastatic soft tissue sarcoma with an LMNA-NTRK1 fusion had rapid and substantial tumor regression with a novel, highly-selective TRK inhibitor, LOXO-101, providing the first clinical evidence of benefit inhibiting TRK fusions.",True,16172727,An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635026/,pmc,1437955200.0,LOXO-101,TRK,"A patient with a metastatic soft tissue sarcoma with an LMNA-NTRK1 fusion had rapid and substantial tumor regression with a novel, highly-selective @entityb$ inhibitor, @entitya$ , providing the first clinical evidence of benefit inhibiting @entityb$ fusions.","[-0.26846865 -0.6569047  -0.6241901  ...  0.10263136  0.24724004
  0.69810253]",37
betahistine,h1,Betahistine is not a full H1 agonist.,True,69019371,TREATMENT OF DISEASES MODULATED BY A H4 RECEPTOR AGONIST,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220130059878%22.PGNR.&OS=DN/20130059878&RS=DN/20130059878,patent_filed,1362614400.0,betahistine,H 1, @entitya$ is not a full @entityb$ agonist.,"[ 0.09739053  0.17729     0.40149823 ...  0.87843716  0.3593399
 -1.0687953 ]",37
3m_052,tlr7,"The HIV-1 gp41-derived antigens anchored in the virosome membrane, along with the adjuvant 3M-052 (TLR7/8 agonist) on the same particle, served as a candidate vaccine for the proof of concept for establishing manufacturing processes, which",True,21833710,New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235025/,pmc,1589760000.0,3M-052,TLR7,"The HIV-1 gp41-derived antigens anchored in the virosome membrane, along with the adjuvant @entitya$ ( @entityb$ /8 agonist) on the same particle, served as a candidate vaccine for the proof of concept for establishing manufacturing processes, which","[-0.40303436 -0.3959716  -0.45333993 ... -0.10647398 -0.28293258
  0.29896733]",1
ly3009120,braf,LY3009120 inhibits the tyrosine kinase KDR with the IC50 of 3.9 μM. [1] Cell Data Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID Assay Methods Test Index PMID Western blot p-EGFR / EGFR / p-BRAF / BRAF /,True,59440299,LY3009120,https://www.selleckchem.com/products/ly3009120.html,selleckchem,,LY3009120,BRaf, @entitya$ inhibits the tyrosine kinase KDR with the IC50 of 3.9 μM. [1] Cell Data Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID Assay Methods Test Index PMID Western blot p-EGFR / EGFR / p-BRAF / @entityb$ /,"[ 0.3055782   0.32857388  0.2813086  ...  0.4640587  -0.78479165
  0.5445425 ]",1
oxaliplatin,oct2,"18 Conversely, organic cation transporter 2 (OCT2), also known as SLC22A2, is a critical determinant in the uptake and consequent cytotoxicity of cisplatin and oxaliplatin.",True,929172,Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527352/,pmc,1438646400.0,oxaliplatin,OCT2,"18 Conversely, organic cation transporter 2 ( @entityb$ ), also known as SLC22A2, is a critical determinant in the uptake and consequent cytotoxicity of cisplatin and @entitya$ .","[-0.5721694  -0.16283742 -0.47904685 ...  0.21331087 -0.5348774
  0.58464545]",32
minocycline,angiostatin,"PNU145156E, 16K prolactin fragment, Linomide (roquinimex), thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, angiostatin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4, ALK1 polypeptides (e.g., dalantercept) or minocycline may be of use in combination with one or more ActRII antagonists.",True,79741805,ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220170240639%22.PGNR.&OS=DN/20170240639&RS=DN/20170240639,patent_filed,1503532800.0,Minocycline,Angiostatin,"PNU145156E, 16K prolactin fragment, Linomide (roquinimex), thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, @entityb$ , cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4, ALK1 polypeptides (e.g., dalantercept) or @entitya$ may be of use in combination with one or more ActRII antagonists.","[-0.14215308  0.20136535  0.5432424  ...  0.62772876 -0.7263542
  0.53378826]",32
loxo_101,trk,"The increase was primarily due to earning a milestone from Loxo Oncology for the advancement of larotrectinib (LOXO-101), the TRK inhibitor for cancer and a milestone from Roche for the advancement of danoprevir, the NS3 protease inhibitor for Hepatitis",True,4170401,ARRAY BIOPHARMA INC | 8-K | 2017-02-09,https://www.sec.gov/Archives/edgar/data/0001100412/0001144204-17-006888.txt,secgov,1486598400.0,LOXO-101,TRK,"The increase was primarily due to earning a milestone from Loxo Oncology for the advancement of larotrectinib ( @entitya$ ), the @entityb$ inhibitor for cancer and a milestone from Roche for the advancement of danoprevir, the NS3 protease inhibitor for Hepatitis","[ 0.13314493 -0.7791802  -0.41044828 ... -0.00833605  0.17659272
  0.38952887]",5
akn-028,flt3,"embodiments, the subject is administered a CAR-expressing cell described herein in combination a FLT3 inhibitor, e.g., sorafenib (Bayer), midostaurin (Novartis), quizartinib (Daiichi Sankyo), crenolanib (Arog Pharmaceuticals), PLX3397 (Daiichi Sankyo), AKN-028 (Akinion Pharmaceuticals), or ASP2215 (Astellas).",True,86508421,Treatment of cancer using GFR α-4 chimeric antigen receptor,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10851149&OS=10851149&RS=10851149,patent_grant,1606780800.0,AKN-028,FLT3,"embodiments, the subject is administered a CAR-expressing cell described herein in combination a @entityb$ inhibitor, e.g., sorafenib (Bayer), midostaurin (Novartis), quizartinib (Daiichi Sankyo), crenolanib (Arog Pharmaceuticals), PLX3397 (Daiichi Sankyo), @entitya$ (Akinion Pharmaceuticals), or ASP2215 (Astellas).","[-0.33457294 -0.06539246 -0.29488724 ...  0.19306616 -0.38460177
  0.9418512 ]",5
loxo_101,trk,"Milestones With respect to product candidates directed to TRK, including LOXO-101 and its back-up compounds, the Company could be required to pay Array up to $222 million in milestone payments, the",True,60048784,"Loxo Oncology, Inc. | 10-Q | 2015-05-14",https://www.sec.gov/Archives/edgar/data/0001581720/0001104659-15-038187.txt,secgov,1431561600.0,LOXO-101,TRK,"Milestones With respect to product candidates directed to @entityb$ , including @entitya$ and its back-up compounds, the Company could be required to pay Array up to $222 million in milestone payments, the","[-0.04756398  0.6517963  -0.5753758  ...  0.00139402  0.4027467
  0.24515985]",17
minocycline,angiostatin,"Examples of angiogenesis inhibitors include, but are not limited to, Angiostatin K1-3, DL-α-Difluoromethyl-ornithine, Endostatin, Fumagillin, Genistein, Minocycline, Staurosporine, (±)-Thalidomide, revlimid, and analogs and derivatives thereof.",True,50929547,Methods for purifying polysaccharides and pharmaceutical compositions and medical devices containing the same,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=09388252&OS=09388252&RS=09388252,patent_grant,1468281600.0,Minocycline,Angiostatin,"Examples of angiogenesis inhibitors include, but are not limited to, @entityb$ K1-3, DL-α-Difluoromethyl-ornithine, Endostatin, Fumagillin, Genistein, @entitya$ , Staurosporine, (±)-Thalidomide, revlimid, and analogs and derivatives thereof.","[-0.02852177 -0.21603602 -0.11393973 ...  0.2748894  -0.12248894
  0.3437606 ]",34
digoxin,ace,"On multivariate analysis when sex, the presence of complications, use of ACE inhibitors, use of aldactone, use of digoxin, frusemide and warfarin and age (age at entering the study) were entered into the analysis, the following",True,108739822,The medical treatment of endomyocardial fibrosis in 2009,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898559/,pmc,1293840000.0,digoxin,ACE,"On multivariate analysis when sex, the presence of complications, use of @entityb$ inhibitors, use of aldactone, use of @entitya$ , frusemide and warfarin and age (age at entering the study) were entered into the analysis, the following","[ 0.10827449 -0.42293793  0.3706153  ... -0.32717544  0.2464133
  0.59354705]",41
oxaliplatin,oct2,"Oxaliplatin is transported mainly by the uptake transporters SLC22A1/OCT1 (OMIM: 602607) and SLC22A2/OCT2 (OMIM: 602608), which play a critical role not only in cellular uptake but also",True,65832541,FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130839/,pmc,1407974400.0,oxaliplatin,OCT2," @entitya$ is transported mainly by the uptake transporters SLC22A1/OCT1 (OMIM: 602607) and SLC22A2/ @entityb$ (OMIM: 602608), which play a critical role not only in cellular uptake but also","[ 0.25238147 -0.9362013  -0.28407854 ... -0.8483867  -0.378963
  0.6352883 ]",41
trifluoperazine,tfp,"( J ) Relative changes in FRET/CFP signals induced by 50 mM KCl, upon 25 μM trifluoperazine (TFP) preincubation.",True,91794649,Voltage-dependent Ca2+ channels promote branching morphogenesis of salivary glands by patterning differential growth,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954160/,pmc,1526342400.0,trifluoperazine,TFP,"( J ) Relative changes in FRET/CFP signals induced by 50 mM KCl, upon 25 μM @entitya$ ( @entityb$ ) preincubation.","[ 0.5812192   0.40739608  0.11750722 ... -0.4480577  -0.22959416
  0.39828557]",33
oxaliplatin,oct2,"Using oxaliplatin as the OCT2 substrate, a number of drugs were identified, including buflomedil, as potent inhibitors (IC 50 <2 μM) of OCT2-mediated oxaliplatin transport.",True,78615386,METHODS OF PREVENTING TOXICITY OF PLATINUM DRUGS,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220180207169%22.PGNR.&OS=DN/20180207169&RS=DN/20180207169,patent_filed,1532563200.0,oxaliplatin,OCT2,"Using @entitya$ as the @entityb$ substrate, a number of drugs were identified, including buflomedil, as potent inhibitors (IC 50 <2 μM) of OCT2-mediated @entitya$ transport.","[-0.32396767 -1.0416285  -0.08420212 ...  0.73069793 -0.55138665
  0.9237151 ]",51
trifluoperazine,tfp,"The calmodulin inhibitor, trifluoperazine (TFP) and other calmodulin inhibitors in the phenothiazine family are currently used for patients with schizophrenia and other diseases.",True,9753793,CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200101083%22.PGNR.&OS=DN/20200101083&RS=DN/20200101083,patent_filed,1585785600.0,trifluoperazine,TFP,"The calmodulin inhibitor, @entitya$ ( @entityb$ ) and other calmodulin inhibitors in the phenothiazine family are currently used for patients with schizophrenia and other diseases.","[-0.94910574 -0.5974701  -0.53985393 ...  0.67447287 -0.6310208
  0.4219383 ]",51
nb001,camp,NB001 Open in a separate window IC 50 values in cAMP accumulation assay in intact transfected HEK293 cells: AC1: 10 μM; AC5: 210 μM; AC6: 170,True,48899298,Inhibitors of Membranous Adenylyl Cyclases,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273670/,pmc,1321488000.0,NB001,cAMP, @entitya$ Open in a separate window IC 50 values in @entityb$ accumulation assay in intact transfected HEK293 cells: AC1: 10 μM; AC5: 210 μM; AC6: 170,"[ 0.08304214 -0.5978586   0.13493025 ...  0.4980665   0.18569931
  0.6043853 ]",11
trifluoperazine,tfp,"Heterogeneity was reduced for three double-blind studies of add-on TCP with trifluoperazine (TFP) vs. TFP-monotherapy and resulted a pooled logOR =0.916 with 95%CI 0.216-1.616 (I 2 negative, no heterogeneity).",True,26881432,Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence.,https://www.ncbi.nlm.nih.gov/pubmed/33651656,pubmed,1614643200.0,trifluoperazine,TFP,"Heterogeneity was reduced for three double-blind studies of add-on TCP with @entitya$ ( @entityb$ ) vs. TFP-monotherapy and resulted a pooled logOR =0.916 with 95%CI 0.216-1.616 (I 2 negative, no heterogeneity).","[-0.359538   -0.47699395  0.5265772  ...  0.49771237  0.82557535
  0.52255625]",2
3m_052,tlr7,"was dissolved in sterile water for achieving the target concentration: About 5 μg of P1, 12 μg of rgp41, and 3 μg of 3M-052 TLR7/8 adjuvant in 0.1 mL. From each animal, pre-immune serum was collected at day 0 and immune serum at day 42 for",True,98231533,New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes,https://www.nature.com/articles/s41541-020-0190-9,nature,1589752800.0,3M-052,TLR7,"was dissolved in sterile water for achieving the target concentration: About 5 μg of P1, 12 μg of rgp41, and 3 μg of @entitya$ @entityb$ /8 adjuvant in 0.1 mL. From each animal, pre-immune serum was collected at day 0 and immune serum at day 42 for","[ 0.20884642 -0.25111884  0.13018073 ... -0.20956133 -0.44773185
  0.29651102]",2
minocycline,angiostatin,"acid inhibitors including indomethacin and sulindac; tetracycline derivatives including minocycline; thalidomide derivatives; 2-methoxyestradiol; tumor necrosis factor-alpha; interferon-gamma-inducible protein 10 (IP-10); interleukin 1 and interleukin 12; interferon alpha, beta or gamma; angiostatin protein or plasminogen fragments; endostatin protein or collagen 18 fragments;",True,78592917,Method of regulating the female reproductive system through angiogenesis inhibitors,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=06441027&OS=06441027&RS=06441027,patent_grant,1030406400.0,Minocycline,Angiostatin,"acid inhibitors including indomethacin and sulindac; tetracycline derivatives including @entitya$ ; thalidomide derivatives; 2-methoxyestradiol; tumor necrosis factor-alpha; interferon-gamma-inducible protein 10 (IP-10); interleukin 1 and interleukin 12; interferon alpha, beta or gamma; @entityb$ protein or plasminogen fragments; endostatin protein or collagen 18 fragments;","[ 0.34315783 -0.13933228 -0.43972915 ...  0.4743134  -0.5474017
  0.8283444 ]",2
minocycline,angiostatin,"Medi-522 (Vitaxin II), CAI, interleukin 12, IM862, amiloride, angiostatin, Kl-3 angiostatin, Kl-5 angiostatin, Captopril, DL-alpha-difluoromethylornithine, DL-alpha-difluoromethylornithine HCl, endostatin, fumagillin, herbimycin A, 4-hydroxyphenylretinamide, juglone, laminin, laminin hexapeptide, laminin pentapeptide, lavendustin A, medroxyprogesterone, minocycline, placenta ribonuclease inhibitor, suramin, thrombospondin, antibodies directed against proangiogenic",True,425222,ANTIBODIES AGAINST THE S100P PROTEIN FOR THE TREATMENT AND DIAGNOSIS OF CANCER,https://data.epo.org/publication-server/rest/v1.2/patents/EP2665746NWB1/document.html,epo,1603839600.0,Minocycline,Angiostatin,"Medi-522 (Vitaxin II), CAI, interleukin 12, IM862, amiloride, @entityb$ , Kl-3 @entityb$ , Kl-5 @entityb$ , Captopril, DL-alpha-difluoromethylornithine, DL-alpha-difluoromethylornithine HCl, endostatin, fumagillin, herbimycin A, 4-hydroxyphenylretinamide, juglone, laminin, laminin hexapeptide, laminin pentapeptide, lavendustin A, medroxyprogesterone, @entitya$ , placenta ribonuclease inhibitor, suramin, thrombospondin, antibodies directed against proangiogenic","[ 0.00896507 -0.04516127  0.04292685 ...  0.9066826  -0.08315937
  0.12693326]",2
3m_052,tlr7,"In one embodiment of any one of the vaccine adjuvant composition, vaccine or method described, the at least one TLR7/8 agonist is selected from the group consisting of gardiquimod, imiquimod, imidazoquinoline compound R848 (resiquimod), VTX-294, 3M-052, CL087, CL097, and CL075.",True,106828552,Vaccine adjuvant compositions,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10881729&OS=10881729&RS=10881729,patent_grant,1609804800.0,3M-052,TLR7,"In one embodiment of any one of the vaccine adjuvant composition, vaccine or method described, the at least one @entityb$ /8 agonist is selected from the group consisting of gardiquimod, imiquimod, imidazoquinoline compound R848 (resiquimod), VTX-294, @entitya$ , CL087, CL097, and CL075.","[-0.9542778  -0.433121    0.03327882 ...  0.24954236 -0.0878775
  0.30006072]",2
3m_052,tlr_7,"The synthetic imidazoquinolinone 3M-052, is structurally similar to resiquimod (R848), a small molecule TLR-7/8 agonist; however, 3M-052 has",True,114340900,"3M-052, a synthetic TLR-7/8 agonist induces durable HIV-1 envelope specific plasma cells and humoral immunity in non-human primates",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109745/,science_immunology,1620604800.0,3M-052,TLR7,"The synthetic imidazoquinolinone @entitya$ , is structurally similar to resiquimod (R848), a small molecule @entityb$ /8 agonist; however, @entitya$ has","[-0.9036014  -0.09960188 -1.0328419  ...  0.9936166  -0.80171925
  0.2776149 ]",8
ly3009120,braf,"As predicted, we show that LY3009120 is more effective than vemurafenib at inhibiting the proliferation of melanoma cells expressing truncated BRAF V600E or RAF1 (",True,65295560,Src-dependent DBL family members drive resistance to vemurafenib in human melanoma,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774858/,pmc,1565827200.0,LY3009120,BRaf,"As predicted, we show that @entitya$ is more effective than vemurafenib at inhibiting the proliferation of melanoma cells expressing truncated @entityb$ V600E or RAF1 (","[ 0.41271266  0.07242425  0.8436408  ...  0.74052244  0.08723801
 -0.18996722]",8
loxo_101,trk,"Upcoming milestones are expected to include: • Continued enrollment of the LOXO-101 Phase 2 global, multi-center, single-arm, open-label basket trial in adult patients with solid tumors that harbor a TRK fusion, with an enrollment update expected in the second half of",True,105030087,Loxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers In AACR Phase 1 Update,https://www.biospace.com/article/releases/loxo-oncology-trk-inhibitor-loxo-101-shows-durable-anti-tumor-activity-across-trk-fusion-cancers-in-aacr-phase-1-update-/,biospace,1460930400.0,LOXO-101,TRK,"Upcoming milestones are expected to include: • Continued enrollment of the @entitya$ Phase 2 global, multi-center, single-arm, open-label basket trial in adult patients with solid tumors that harbor a @entityb$ fusion, with an enrollment update expected in the second half of","[-0.2989222  -0.12159918 -0.50040865 ... -0.5315605  -0.00924725
  0.61910224]",8
ly3009120,braf,"prevalence of KRAS and BRAF mutations in CRC [ 39 ], as well as the involvement of the aforementioned mutations in acquired resistance to therapy [ 40 ] we hypothesized that a panRAF inhibitor like LY3009120 would have preclinical activity in this tumor setting.",True,44961836,"LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354729/,pmc,1481846400.0,LY3009120,BRaf,"prevalence of KRAS and @entityb$ mutations in CRC [ 39 ], as well as the involvement of the aforementioned mutations in acquired resistance to therapy [ 40 ] we hypothesized that a panRAF inhibitor like @entitya$ would have preclinical activity in this tumor setting.","[ 0.02301254 -0.2954671   0.48934966 ...  0.21427226  0.87915385
  0.14676952]",8
digoxin,ace,"(aspirin, Cox-2 inhibitors, and other nonsteroidal inflammatory medications), steroids, beta-blockers (± diuretics), ACE inhibitors (± diuretics), ARBs (± diuretics), any diuretic alone (including potassium-sparking diuretics), leukotriene antagonists, and digoxin.",True,82789640,"Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: MESA",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860615/,pmc,1459814400.0,digoxin,ACE,"(aspirin, Cox-2 inhibitors, and other nonsteroidal inflammatory medications), steroids, beta-blockers (± diuretics), @entityb$ inhibitors (± diuretics), ARBs (± diuretics), any diuretic alone (including potassium-sparking diuretics), leukotriene antagonists, and @entitya$ .","[ 0.12175793  0.11450327 -0.36279148 ...  0.03945879 -0.08236037
  0.53116125]",8
minocycline,angiostatin,"Medi-522 (Vitaxin II), CAI, interleukin 12, IM862, amiloride, angiostatin, Kl-3 angiostatin, Kl-5 angiostatin, Captopril, DL-alpha-difluoromethylornithine, DL-alpha-difluoromethylornithine HCl, endostatin, fumagillin, herbimycin A, 4-Hydroxyphenylretinamide, juglone, laminin, laminin hexapeptide, laminin pentapeptide, lavendustin A, medroxyprogesterone, minocycline, placenta ribonuclease inhibitor, suramin, thrombospondin, antibodies directed against proangiogenic",True,3252534,METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER,https://data.epo.org/publication-server/rest/v1.2/patents/EP3545966NWA1/document.html,epo,1569967200.0,Minocycline,Angiostatin,"Medi-522 (Vitaxin II), CAI, interleukin 12, IM862, amiloride, @entityb$ , Kl-3 @entityb$ , Kl-5 @entityb$ , Captopril, DL-alpha-difluoromethylornithine, DL-alpha-difluoromethylornithine HCl, endostatin, fumagillin, herbimycin A, 4-Hydroxyphenylretinamide, juglone, laminin, laminin hexapeptide, laminin pentapeptide, lavendustin A, medroxyprogesterone, @entitya$ , placenta ribonuclease inhibitor, suramin, thrombospondin, antibodies directed against proangiogenic","[ 0.00896507 -0.04516127  0.04292685 ...  0.9066826  -0.08315937
  0.12693326]",9
ly3009120,braf,"Ponatinib inhibited BRAF V600E (IC 50 = 14 nM) and BRAF WT (IC 50 = 278 nM) comparably to Vemurafenib, Dabrafenib, and Encorafenib inhibitors but also to LY3009120, AZ-628, and TAK-632 that inhibit both monomers and dimers (Fig. 1h and Supplementary Fig. 5 ) 11 , 12 .",True,4901799,Inhibitors of BRAF dimers using an allosteric site,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462985/,pmc,1598918400.0,LY3009120,BRAF,"Ponatinib inhibited @entityb$ V600E (IC 50 = 14 nM) and @entityb$ WT (IC 50 = 278 nM) comparably to Vemurafenib, Dabrafenib, and Encorafenib inhibitors but also to @entitya$ , AZ-628, and TAK-632 that inhibit both monomers and dimers (Fig. 1h and Supplementary Fig. 5 ) 11 , 12 .","[ 0.3409084  -0.11361994 -0.07315936 ... -0.23569185 -0.22101137
  0.33926404]",9
thyroxine,thyroid hormone receptor,"The thyroid hormone receptor beta (THR‐β) is the predominant liver thyroxine (T4) receptor, through which increased cholesterol metabolism and excretion through bile is mediated.",True,109171188,Review article: new treatments in non-alcoholic fatty liver disease.,https://www.ncbi.nlm.nih.gov/pubmed/28677333,pubmed,1496095200.0,thyroxine,thyroid hormone receptor,"The @entityb$ beta (THR‐β) is the predominant liver @entitya$ (T4) receptor, through which increased cholesterol metabolism and excretion through bile is mediated.","[-0.4271923   0.2153202  -0.65618366 ...  0.0913812  -0.5950875
 -0.10799852]",9
medi9197,pd_l1,"This first-time-in-human, phase 1 study evaluated MEDI9197 with or without the programmed cell death ligand-1 (PD-L1) inhibitor",True,12619670,Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors,https://doaj.org/article/1cea92e961774c018a7c1b71c547d92b,doaj,1602334871.0,MEDI9197,PD-L1,"This first-time-in-human, phase 1 study evaluated @entitya$ with or without the programmed cell death ligand-1 ( @entityb$ ) inhibitor","[-0.70710254 -0.39025548 -0.8087465  ...  0.29884085 -0.04050563
  0.43172157]",9
loxo_101,trk,"Loxo and granted Loxo exclusive rights to develop and commercialize certain Array-invented compounds targeted at the tropomyosin kinase (""Trk"") family of receptors, including LOXO-101, which is currently in Phase 1 and Phase 2 clinical trials.",True,80368843,ARRAY BIOPHARMA INC | 10-K | 2016-08-19,https://www.sec.gov/Archives/edgar/data/0001100412/0001100412-16-000048.txt,secgov,1471564800.0,LOXO-101,TRK,"Loxo and granted Loxo exclusive rights to develop and commercialize certain Array-invented compounds targeted at the tropomyosin kinase ("" @entityb$ "") family of receptors, including @entitya$ , which is currently in Phase 1 and Phase 2 clinical trials.","[-0.5709572  -0.14272773 -0.41239572 ... -0.11287337  0.13310742
  1.3153797 ]",9
ly3009120,braf,"Similarly, Peng et al reported the development of LY3009120, a pan-RAF inhibitor that binds simultaneously to two sites of BRAF dimers and equally inhibits all RAF isoforms (ARAF, BRAF, CRAF) with similar affinity [ 25 – 29 ].",True,92953300,Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR -mutated lung cancers,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486868/,pmc,1551398400.0,LY3009120,BRaf,"Similarly, Peng et al reported the development of @entitya$ , a pan-RAF inhibitor that binds simultaneously to two sites of @entityb$ dimers and equally inhibits all RAF isoforms (ARAF, @entityb$ , CRAF) with similar affinity [ 25 – 29 ].","[-0.7187324  -0.3205457   0.29959294 ...  0.5147854  -0.25175652
 -0.02621208]",14
minocycline,angiostatin,"SU11248 (Sunitinib malate), VEGF-Trap, XL184, ZD6474, ATN-161, EMD 121974 (Cilenigtide), Celecoxib, Angiostatin, Endostatin, Regranex, Apligraf, Paclitaxel, tetracyclines, clarithromycin, lasix, captopril, aspirin, Vitamin D3 analogs, retinoids, Imiquomod, Interferon alfa2a, Minocycline, copper peptide containing dressings, Lucentis™, ATG002, Pegaptanib Sodium, Tryptophanyl-tRNA synthetase, squalamine lactate,",True,60553969,ANGIOGENESIS INHIBITORS,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220120190659%22.PGNR.&OS=DN/20120190659&RS=DN/20120190659,patent_filed,1343260800.0,Minocycline,Angiostatin,"SU11248 (Sunitinib malate), VEGF-Trap, XL184, ZD6474, ATN-161, EMD 121974 (Cilenigtide), Celecoxib, @entityb$ , Endostatin, Regranex, Apligraf, Paclitaxel, tetracyclines, clarithromycin, lasix, captopril, aspirin, Vitamin D3 analogs, retinoids, Imiquomod, Interferon alfa2a, @entitya$ , copper peptide containing dressings, Lucentis™, ATG002, Pegaptanib Sodium, Tryptophanyl-tRNA synthetase, squalamine lactate,","[ 0.22931132  0.20528841 -0.15262549 ...  0.31773257 -0.13730101
  0.38687187]",14
ly3009120,braf,"study, we found that combinatory treatment with LY3009120 and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS , NRAS or BRAF mutation at the doses of two drugs",True,110652918,RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1,https://www.nature.com/articles/onc2017384,nature,1508709600.0,LY3009120,BRAF,"study, we found that combinatory treatment with @entitya$ and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS , NRAS or @entityb$ mutation at the doses of two drugs","[ 0.7494477  -0.38679656  0.6112379  ...  0.529278   -0.04733681
  0.50773686]",14
ly3009120,braf,"cited by applicant Henry et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.",True,99491087,Inhibitors of RAF kinases,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10927111&OS=10927111&RS=10927111,patent_grant,1614038400.0,LY3009120,BRAF,"cited by applicant Henry et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea ( @entitya$ ) as a pan-RAF inhibitor with minimal paradoxical activation and activity against @entityb$ or RAS mutant tumor cells.","[ 0.0423195  -0.36543486  0.88468456 ...  0.19683506  0.04962851
  0.18724275]",14
trifluoperazine,tfp,"Trifluoperazine (TFP) is used as an antipsychotic and an antiemetic, and it has been found to inhibit lung CSC spheroid formation ability",True,69247000,Emerging agents that target signaling pathways in cancer stem cells,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249421/,pmc,1590451200.0,trifluoperazine,TFP," @entitya$ ( @entityb$ ) is used as an antipsychotic and an antiemetic, and it has been found to inhibit lung CSC spheroid formation ability","[-0.3207992  -0.10503367 -0.28531095 ... -0.05508311 -0.11061683
 -0.3683786 ]",14
3m_052,tlr7,"Example includes imidazoquinoline family of TLR7/8 Ligands (e.g. imiquimod(R837), gardiquimod, resiquimod (R848), 3M-052, 3M-852, 3M-S-34240), CpG ODNs such as ODN 1826 and ODN 2216, TLR agonist including TLR peptide agonist",True,87074894,Methods and agents to treat tumor cells and cancer,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220190160174%22.PGNR.&OS=DN/20190160174&RS=DN/20190160174,patent_filed,1559174400.0,3M-052,TLR7,"Example includes imidazoquinoline family of @entityb$ /8 Ligands (e.g. imiquimod(R837), gardiquimod, resiquimod (R848), @entitya$ , 3M-852, 3M-S-34240), CpG ODNs such as ODN 1826 and ODN 2216, TLR agonist including TLR peptide agonist","[-0.9276796  -0.11024384 -1.0172722  ...  0.07344787 -0.32587114
  0.74768364]",15
nalbuphine,mor,"compare effects on ICSS produced by repeated daily treatment with MOR agonists that ranged from low to high efficacy in stimulating MOR-coupled G-protein signaling (from lowest to highest efficacy: NAQ, nalbuphine, buprenorphine, fentanyl, methadone) ( Emmerson et al., 1996 ; Li",True,18447144,Role of Agonist Efficacy in Exposure-Induced Enhancement of Mu Opioid Reward in Rats,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500752/,pmc,1552521600.0,nalbuphine,MOR,"compare effects on ICSS produced by repeated daily treatment with @entityb$ agonists that ranged from low to high efficacy in stimulating MOR-coupled G-protein signaling (from lowest to highest efficacy: NAQ, @entitya$ , buprenorphine, fentanyl, methadone) ( Emmerson et al., 1996 ; Li","[ 0.46836293 -0.15363279 -0.4680347  ...  0.08767208  0.06584074
  0.8247359 ]",15
ly3009120,braf,"searching of cell line databases identified one additional cell line, OV-90, an ovarian adenocarcinoma with a similar BRAF N486-P490 deletion, and sensitive to LY3009120, but not vemurafenib.",True,62900787,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,https://www.ncbi.nlm.nih.gov/pubmed/26732095,pubmed,1459288800.0,LY3009120,BRAF,"searching of cell line databases identified one additional cell line, OV-90, an ovarian adenocarcinoma with a similar @entityb$ N486-P490 deletion, and sensitive to @entitya$ , but not vemurafenib.","[-0.21762203  0.23850948 -0.3965569  ... -0.2503874   0.5402196
  0.40898016]",15
digoxin,ace,"result discussed above may lead the physician to continue, increase, or modify treatment (e.g., increase the dosage of diuretic, ACE inhibitor, digoxin, β-blocker, calcium channel blocker, and/or vasodialtor, or even consider surgical intervention) because of the false impression that current therapy",True,110755034,Methods and compositions for measuring natriuretic peptides and uses thereof,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=07524635&OS=07524635&RS=07524635,patent_grant,1240876800.0,digoxin,ACE,"result discussed above may lead the physician to continue, increase, or modify treatment (e.g., increase the dosage of diuretic, @entityb$ inhibitor, @entitya$ , β-blocker, calcium channel blocker, and/or vasodialtor, or even consider surgical intervention) because of the false impression that current therapy","[ 0.8371502  -0.34189335 -0.30001703 ... -0.318434    0.45971522
  0.22023621]",15
trifluoperazine,tfp,"junctions, we exposed guinea-pig seminiferous tubules to the presence of a Ca2+ chelator (EGTA) and to a calmodulin blocker (Trifluoperazine, TFP) in vitro, for times ranging from 30 to 120 min.",True,88394587,Evidence that a Ca2+ chelator and a calmodulin blocker interfere with the structure of inter-Sertoli junctions.,https://www.ncbi.nlm.nih.gov/pubmed/3923652,pubmed,486252000.0,trifluoperazine,TFP,"junctions, we exposed guinea-pig seminiferous tubules to the presence of a Ca2+ chelator (EGTA) and to a calmodulin blocker ( @entitya$ , @entityb$ ) in vitro, for times ranging from 30 to 120 min.","[ 0.02416669  0.09992489 -0.0191389  ...  0.01768691 -0.71277755
  0.5077761 ]",15
flurazepam,gaba_a receptor,"kinetics [ 145 ] Enasidenib Acute myeloid leukemia Inhibitor IDH2 In silico: Binding free energy, conformational change [ 146 ] Flurazepam Insomnia Activator GABA-A receptor Site-directed mutagenesis.",True,47797217,Integrated Computational Approaches and Tools for Allosteric Drug Discovery,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036869/,pmc,1580169600.0,Flurazepam,GABA A Receptor,"kinetics [ 145 ] Enasidenib Acute myeloid leukemia Inhibitor IDH2 In silico: Binding free energy, conformational change [ 146 ] @entitya$ Insomnia Activator @entityb$ Site-directed mutagenesis.","[-0.45171398  0.02128632 -0.12454128 ...  0.6887835  -0.21927245
  0.9809748 ]",18
digoxin,ace,Our experience suggests that treatment of anthracycline-induced CHF with an ACE inhibitor should start soon after clinical improvement on digoxin/diuretic regardless of the severity of symptoms rather than waiting for clinical deterioration.,True,61263166,Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.,https://www.ncbi.nlm.nih.gov/pubmed/8569365,pubmed,823302000.0,digoxin,ACE,Our experience suggests that treatment of anthracycline-induced CHF with an @entityb$ inhibitor should start soon after clinical improvement on @entitya$ /diuretic regardless of the severity of symptoms rather than waiting for clinical deterioration.,"[ 0.3914903   0.13333088 -0.2349392  ...  0.32049716  0.0412574
 -0.07984693]",18
ly3009120,braf,"Thus, for the avoidance of doubt, where vemurafenib, dabrafenib, sorafenib, encorafenib, RAF265, AD80, GDC0879, AZ628, ZM336372, NVPBHG712, LY3009120, TAK632, MLN2480, or XP102 is referenced, it is disclosed that BRAF inhibitors can be used generally or other specific types of BRAF inhibitors can also be used.",True,32886624,Combinations to treat cancer,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10869879&OS=10869879&RS=10869879,patent_grant,1608595200.0,LY3009120,BRAF,"Thus, for the avoidance of doubt, where vemurafenib, dabrafenib, sorafenib, encorafenib, RAF265, AD80, GDC0879, AZ628, ZM336372, NVPBHG712, @entitya$ , TAK632, MLN2480, or XP102 is referenced, it is disclosed that @entityb$ inhibitors can be used generally or other specific types of @entityb$ inhibitors can also be used.","[-0.50998026 -0.16721089  0.00072219 ...  0.5987673  -0.24249412
  0.4867233 ]",18
ly3009120,braf,"ChEMBL 1495613 In vivo inhibition of BRAF V600E mutant in human A375 cells xenografted in po dosed athymic nu/nu mouse assessed as inhibition of ERK phosphorylation by ELISA Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.",True,25608730,In vivo inhibition of BRAF V600E mutant in human A375 cells xenografted in po dosed athymic nu/nu mouse assessed as inhibition of ERK phosphorylation by ELISA,https://pubchem.ncbi.nlm.nih.gov/bioassay/1226881,bioassay,,LY3009120,BRaf,"ChEMBL 1495613 In vivo inhibition of @entityb$ V600E mutant in human A375 cells xenografted in po dosed athymic nu/nu mouse assessed as inhibition of ERK phosphorylation by ELISA Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea ( @entitya$ ) as a pan-RAF inhibitor with minimal paradoxical activation and activity against @entityb$ or RAS mutant tumor cells.","[ 0.01848013 -0.12105118  0.08855572 ...  0.18253313 -0.27890387
  0.3749621 ]",18
digoxin,ace,"agents for treating heart failure selected from the group consisting of an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), a beta-blocker, digoxin, a diuretic, a blood vessel dilator, potassium, magnesium, an aldactone inhibitor, a calcium channel blocker,",True,91864766,AGONISTS OF HYPOCRETIN RECEPTOR 2 FOR USE FOR TREATING HEART FAILURE,https://data.epo.org/publication-server/rest/v1.2/patents/EP3068783NWB1/document.html,epo,1600812000.0,digoxin,ACE,"agents for treating heart failure selected from the group consisting of an angiotensin converting enzyme ( @entityb$ ) inhibitor, an angiotensin II receptor blocker (ARB), a beta-blocker, @entitya$ , a diuretic, a blood vessel dilator, potassium, magnesium, an aldactone inhibitor, a calcium channel blocker,","[-0.10019322 -0.17455061 -0.37640932 ...  0.50909394 -0.5619605
  0.08931942]",18
3m_052,tlr7,"In certain embodiments, the TLR7/8 agonist is a compound of the following structure or pharmaceutically acceptable salts thereof: In certain preferred embodiments, a TLR7/8 agonist used in the compositions herein comprises a N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide), 3M-052 as described in U.S. Pat.",True,90468986,Formulation Containing TLR Agonist and Methods of Use,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220190142935%22.PGNR.&OS=DN/20190142935&RS=DN/20190142935,patent_filed,1557964800.0,3M-052,TLR7,"In certain embodiments, the @entityb$ /8 agonist is a compound of the following structure or pharmaceutically acceptable salts thereof: In certain preferred embodiments, a @entityb$ /8 agonist used in the compositions herein comprises a N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide), @entitya$ as described in U.S. Pat.","[-0.7765491   0.0397518   0.0522378  ...  0.5802904  -0.6207236
  0.41361725]",21
thyroxine,thyroid hormone receptor,"cited by applicant Davis et al., “Thyroxine Promotes Association of Mitogen-activated Protein Kinase and Nuclear Thyroid Hormone Receptor (TR) and Causes Serine Phosphorylation of TR”, J. Biol.",True,113374699,Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=10961204&OS=10961204&RS=10961204,patent_grant,1617062400.0,thyroxine,thyroid hormone receptor,"cited by applicant Davis et al., “ @entitya$ Promotes Association of Mitogen-activated Protein Kinase and Nuclear @entityb$ (TR) and Causes Serine Phosphorylation of TR”, J. Biol.","[-0.59899175 -0.84876835 -0.12319385 ...  0.33448252  0.6463188
  0.5624572 ]",21
ly3009120,braf,"Examination of an additional BRAF mut xenograft model, HT-29, confirmed the in vivo efficacy of LY3009120 (delta(T/C)= 40%, p < 0.001) in a BRAF mut CRC setting (Figure ​ (Figure5A, 5A , lower left panel ), while LY3009120-treatment of Colo 320HSR ( KRAS WT /BRAF WT ) indicated lack of in vivo efficacy in a KRAS WT /BRAF WT xenograft model (Figure ​ (Figure5A, 5A , lower right panel ).",True,44961836,"LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354729/,pmc,1481846400.0,LY3009120,BRAF,"Examination of an additional @entityb$ mut xenograft model, HT-29, confirmed the in vivo efficacy of @entitya$ (delta(T/C)= 40%, p < 0.001) in a @entityb$ mut CRC setting (Figure ​ (Figure5A, 5A , lower left panel ), while LY3009120-treatment of Colo 320HSR ( KRAS WT / @entityb$ WT ) indicated lack of in vivo efficacy in a KRAS WT / @entityb$ WT xenograft model (Figure ​ (Figure5A, 5A , lower right panel ).","[ 0.19076854 -0.3191792   0.22623152 ... -0.27657175  0.47939444
 -0.89116687]",21
loxo_101,trk,"Six patients, all with TRK fusion cancers unresponsive to current therapies, reported tumor shrinkage following treatment with Loxo's drug LOXO-101.",True,74533818,Loxo Cancer Drug Targets Gene Mutation With Durable Responses in Early Study,https://www.thestreet.com/story/13533127/1/loxo-cancer-drug-targets-gene-mutation-with-durable-responses-in-early-study.html,thestreet,1460909820.0,LOXO-101,TRK,"Six patients, all with @entityb$ fusion cancers unresponsive to current therapies, reported tumor shrinkage following treatment with Loxo's drug @entitya$ .","[ 0.3812212  -0.96197975 -0.29266343 ...  0.4324265   0.32922232
  0.35023227]",21
tesamorelin,growth hormone releasing factor,"octreotide (C2L), octreotide QLT, octreotide LAR, Sandostatin LAR, SomaLAR, Somatuline (lanreotide), see, e.g., Deghenghi et al. Endocrine 14:29 ; TH9507 (Tesamorelin, a growth hormone-releasing factor); POL7080 (a protegrin analog, an anti-microbial peptide); relaxin; a corticotropin releasing factor agonist such as urotensin, sauvagine, and",True,40496034,HYDRAZINYL-INDOLE COMPOUNDS AND CONJUGATES,https://data.epo.org/publication-server/rest/v1.2/patents/EP2920167NWB1/document.html,epo,1571176800.0,Tesamorelin,Growth Hormone-Releasing Factor,"octreotide (C2L), octreotide QLT, octreotide LAR, Sandostatin LAR, SomaLAR, Somatuline (lanreotide), see, e.g., Deghenghi et al. Endocrine 14:29 ; TH9507 ( @entitya$ , a @entityb$ ); POL7080 (a protegrin analog, an anti-microbial peptide); relaxin; a corticotropin releasing factor agonist such as urotensin, sauvagine, and","[ 0.1906415  -0.16620876  0.01790985 ...  0.8628809  -0.7451884
  0.8753789 ]",21
betahistine,h_1,poisoning Histamine antagonist References External links DrugBank EXPT01785 Histamine and Histamine intolerance v t e Histamine receptor modulators H 1 Agonists: 2-Pyridylethylamine Betahistine Histamine HTMT L -Histidine UR-AK49 Antagonists: First-generation: 4-Methyldiphenhydramine Alimemazine Antazoline Azatadine Bamipine Benzatropine (benztropine) Bepotastine Bromazine Brompheniramine Buclizine Captodiame,True,83321,Histamine,https://www.wikidoc.org/index.php/Histamine,wikidoc,,betahistine,H 1,poisoning Histamine antagonist References External links DrugBank EXPT01785 Histamine and Histamine intolerance v t e Histamine receptor modulators @entityb$ Agonists: 2-Pyridylethylamine @entitya$ Histamine HTMT L -Histidine UR-AK49 Antagonists: First-generation: 4-Methyldiphenhydramine Alimemazine Antazoline Azatadine Bamipine Benzatropine (benztropine) Bepotastine Bromazine Brompheniramine Buclizine Captodiame,"[-0.8563395  -0.06164317  0.17927371 ...  0.88075    -0.49902803
 -0.08784653]",23
minocycline,angiostatin,"herbimycin A, PNU145156E, 16K prolactin fragment, Linomide (roquinimex), thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, angiostatin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 or minocycline may be of use.",True,43018280,Strategies for improved cancer vaccines,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=08562988&OS=08562988&RS=08562988,patent_grant,1382400000.0,Minocycline,Angiostatin,"herbimycin A, PNU145156E, 16K prolactin fragment, Linomide (roquinimex), thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, @entityb$ , cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 or @entitya$ may be of use.","[ 0.10675035  0.13392891  0.6461922  ...  0.4957294  -0.30910027
  0.34856427]",23
ly3009120,braf,"(A) cUC cells (Sora) were treated with vehicle (dimethyl sulfoxide; Cont) and inhibitors of BRAF (Dabrafenib; Dab), pan-RAF (LY3009120; LY), MEK (PD0325901; PD), and ERK (SCH772984; SCH) at 1 μM for indicated time.",True,101691859,Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma,https://www.biorxiv.org/content/10.1101/786095v1,biorxiv,1569880800.0,LY3009120,BRaf,"(A) cUC cells (Sora) were treated with vehicle (dimethyl sulfoxide; Cont) and inhibitors of @entityb$ (Dabrafenib; Dab), pan-RAF ( @entitya$ ; LY), MEK (PD0325901; PD), and ERK (SCH772984; SCH) at 1 μM for indicated time.","[-0.4788009   0.32407334  0.07464536 ... -0.76164335 -0.49761128
  0.62455237]",23
minocycline,angiostatin,"Medi-522 (Vitaxin II), CAI, interleukin 12, IM862, amiloride, angiostatin, Kl-3 angiostatin, Kl-5 angiostatin, Captopril, DL-alpha-difluoromethylornithine, DL-alpha-difluoromethylornithine HCl, endostatin, fumagillin, herbimycin A, 4-hydroxyphenylretinamide, juglone, laminin, laminin hexapeptide, laminin pentapeptide, lavendustin A, medroxyprogesterone, minocycline, placenta ribonuclease inhibitor, suramin, thrombospondin, antibodies directed against proangiogenic",True,104273493,S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF,https://data.epo.org/publication-server/rest/v1.2/patents/EP2580240NWB1/document.html,epo,1543359600.0,Minocycline,Angiostatin,"Medi-522 (Vitaxin II), CAI, interleukin 12, IM862, amiloride, @entityb$ , Kl-3 @entityb$ , Kl-5 @entityb$ , Captopril, DL-alpha-difluoromethylornithine, DL-alpha-difluoromethylornithine HCl, endostatin, fumagillin, herbimycin A, 4-hydroxyphenylretinamide, juglone, laminin, laminin hexapeptide, laminin pentapeptide, lavendustin A, medroxyprogesterone, @entitya$ , placenta ribonuclease inhibitor, suramin, thrombospondin, antibodies directed against proangiogenic","[ 0.00896507 -0.04516127  0.04292685 ...  0.9066826  -0.08315937
  0.12693326]",23
minocycline,angiostatin,"including indomethacin and sulindac; tetracycline derivatives including minocycline; thalidomide and thalidomide analogs and derivatives; 2-methoxyestradiol; tumor necrosis factor-alpha; interferon-gamma-inducible protein 10 (IP-10); interleukin 1 and interleukin 12; interferon alpha, beta or gamma; angiostatin protein or plasminogen fragments; endostatin protein or collagen",True,7759759,METHODS FOR OPTIMIZING ELECTROPORATION,https://data.epo.org/publication-server/rest/v1.2/patents/EP2310500NWB1/document.html,epo,1426028400.0,Minocycline,Angiostatin,"including indomethacin and sulindac; tetracycline derivatives including @entitya$ ; thalidomide and thalidomide analogs and derivatives; 2-methoxyestradiol; tumor necrosis factor-alpha; interferon-gamma-inducible protein 10 (IP-10); interleukin 1 and interleukin 12; interferon alpha, beta or gamma; @entityb$ protein or plasminogen fragments; endostatin protein or collagen","[ 0.58189964 -0.36997172 -0.26479992 ...  0.33285424 -0.39891037
  0.8531903 ]",23
3m_052,tlr7,"TLR7 may be activated by imidazoquinolines, such as imiquimod, resiquimod and derivatives imiquimod or resiquimod ( e.g. 3M-052).",True,16801329,FORMULATION OF A PEPTIDE VACCINE,https://data.epo.org/publication-server/rest/v1.2/patents/EP3552623NWA1/document.html,epo,1571176800.0,3M-052,TLR7," @entityb$ may be activated by imidazoquinolines, such as imiquimod, resiquimod and derivatives imiquimod or resiquimod ( e.g. @entitya$ ).","[-0.84829396 -0.12671363 -0.4529717  ...  0.29081276 -0.69751847
  0.31077197]",24
betahistine,h1,"rotational behavior in UL rats; iii) the more potent H3 antagonists, thioperamide and GT-2016, were more efficacious than betahistine, a mixed H3 antagonist and H1 agonist.",True,21193263,Histaminergic ligands attenuate barrel rotation in rats following unilateral labyrinthectomy.,https://www.ncbi.nlm.nih.gov/pubmed/10022031,pubmed,912380400.0,betahistine,H 1,"rotational behavior in UL rats; iii) the more potent H3 antagonists, thioperamide and GT-2016, were more efficacious than @entitya$ , a mixed H3 antagonist and @entityb$ agonist.","[ 0.7795231   0.24973208  0.65355515 ...  0.5210657  -0.32361984
  0.58241975]",24
ly3009120,braf,"rat at 10 mg/kg administered as suspension in 20% cyclodextrin Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.",True,16578216,Oral bioavailability in Sprague-Dawley rat at 10 mg/kg administered as suspension in 20% cyclodextrin,https://pubchem.ncbi.nlm.nih.gov/bioassay/1226928,bioassay,,LY3009120,BRaf,"rat at 10 mg/kg administered as suspension in 20% cyclodextrin Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea ( @entitya$ ) as a pan-RAF inhibitor with minimal paradoxical activation and activity against @entityb$ or RAS mutant tumor cells.","[ 0.8163238  -0.21876672  0.23417233 ...  0.21164851 -0.4773861
  0.48169166]",24
trifluoperazine,tfp,"Application of EGTA, a Ca2+ chelator, and trifluoperazine dihydrochloride (TFP), a calmodulin (CaM) antagonist, markedly suppressed the generation of H2O2, affected foot cell and conidiophore development and reduced conidia",True,36869470,Transcriptome Analyses Shed New Insights into Primary Metabolism and Regulation of Blumeria graminis f. sp. tritici during Conidiation,https://doaj.org/article/6fb9988ec5a345e09a9db3669c7b7c1c,doaj,1498827324.0,trifluoperazine,TFP,"Application of EGTA, a Ca2+ chelator, and @entitya$ dihydrochloride ( @entityb$ ), a calmodulin (CaM) antagonist, markedly suppressed the generation of H2O2, affected foot cell and conidiophore development and reduced conidia","[ 0.13823512  0.13439766  0.3853782  ...  0.47011167 -0.8402649
  0.22975038]",24
trifluoperazine,tfp,The researchers used an already-licensed anti-psychotic medicine -- trifluoperazine (TFP) -- to alter the behaviour of tiny water channel 'pores' in cells known as aquaporins.,True,6245010,'Cell pores' discovery gives hope to millions of brain and spinal cord injury patients,https://www.sciencedaily.com/releases/2020/05/200514115824.htm,sciencedaily,1589407200.0,trifluoperazine,TFP,The researchers used an already-licensed anti-psychotic medicine -- @entitya$ ( @entityb$ ) -- to alter the behaviour of tiny water channel 'pores' in cells known as aquaporins.,"[-0.30952445 -0.19013177 -0.592286   ...  0.56758624 -0.04502566
  1.0212755 ]",24
trifluoperazine,tfp,1B is a diagram illustrating results of cytokine release tests for Trifluoperazine (TFP) in the embodiment 1 of the present invention.,True,45315337,TREATMENT OF CYTOKINE RELEASE SYNDROME BY DECREASING LEVEL OF PROINFLAMMATORY CYTOKINE,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200188465%22.PGNR.&OS=DN/20200188465&RS=DN/20200188465,patent_filed,1592438400.0,trifluoperazine,TFP,1B is a diagram illustrating results of cytokine release tests for @entitya$ ( @entityb$ ) in the embodiment 1 of the present invention.,"[-0.09706212 -0.4436837  -0.65508    ...  0.08426946 -0.24271733
  0.7088621 ]",28
ly3009120,braf,"searching of cell line databases identified one additional cell line, OV-90, an ovarian adenocarcinoma with a similar BRAF N486-P490 deletion, and sensitive to LY3009120, but not vemurafenib.",True,62900787,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,https://www.ncbi.nlm.nih.gov/pubmed/26732095,pubmed,1459288800.0,LY3009120,BRaf,"searching of cell line databases identified one additional cell line, OV-90, an ovarian adenocarcinoma with a similar @entityb$ N486-P490 deletion, and sensitive to @entitya$ , but not vemurafenib.","[-0.21762224  0.23850927 -0.39655724 ... -0.25038734  0.54021984
  0.4089803 ]",28
ly3009120,braf,"some embodiments, the MEK inhibitors can also be combined or administered with the BRAF inhibitors (e.g., vemurafenib, dabrafenib, sorafenib, encorafenib, RAF265, AD80, GDC0879, AZ628, ZM336372, NVPBHG712, LY3009120, TAK632, MLN2480, or XP102) and the DNA damaging agents as described herein.",True,5229459,COMBINATIONS TO TREAT CANCER,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200046749%22.PGNR.&OS=DN/20200046749&RS=DN/20200046749,patent_filed,1581552000.0,LY3009120,BRaf,"some embodiments, the MEK inhibitors can also be combined or administered with the @entityb$ inhibitors (e.g., vemurafenib, dabrafenib, sorafenib, encorafenib, RAF265, AD80, GDC0879, AZ628, ZM336372, NVPBHG712, @entitya$ , TAK632, MLN2480, or XP102) and the DNA damaging agents as described herein.","[ 0.05996263 -0.81405383  0.28383043 ... -0.07356036  0.4941915
  0.738042  ]",28
loxo_101,trk,"We believe that these characteristics of LOXO-101 may allow us to dose higher in humans, achieve greater inhibition of the TRK target",True,58357551,"Loxo Oncology, Inc. | 424B4 | 2014-08-01",https://www.sec.gov/Archives/edgar/data/0001581720/0001047469-14-006588.txt,secgov,1406851200.0,LOXO-101,TRK,"We believe that these characteristics of @entitya$ may allow us to dose higher in humans, achieve greater inhibition of the @entityb$ target","[ 0.2170915  -0.72545785  0.3001115  ... -0.07740187 -0.5039066
  0.02608122]",28
tesamorelin,growth hormone releasing factor,"Similarly, the growth hormone-releasing factor tesamorelin has been shown to decrease VAT and improve lipids in HIV-infected patients with milder side effects than growth hormone, but",True,56236814,"A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597631/,pmc,1363219200.0,Tesamorelin,Growth Hormone-Releasing Factor,"Similarly, the @entityb$ @entitya$ has been shown to decrease VAT and improve lipids in HIV-infected patients with milder side effects than growth hormone, but","[ 0.5525626  -0.11568756 -0.0899242  ... -0.27497697  0.16005047
  0.15574688]",28
ly3009120,braf,We found LY3009120 to be very active against cell lines with BRAF fusions as a single agent.,True,92953300,Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR -mutated lung cancers,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486868/,pmc,1551398400.0,LY3009120,BRAF,We found @entitya$ to be very active against cell lines with @entityb$ fusions as a single agent.,"[-1.2675656  -1.323211   -0.06921566 ...  0.58137155  0.12348834
  1.4097444 ]",29
3m_052,tlr_7,The TLR 7/8 agonist 3M-052 was provided by 3M.,True,95758779,Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301946/,pmc,1484179200.0,3M-052,TLR7,The @entityb$ /8 agonist @entitya$ was provided by 3M.,"[-0.6426239  -0.17140162 -0.8391382  ... -0.19903725 -0.02400613
  1.0053152 ]",29
3m_052,tlr7,wherein the liposome comprises a TLR4 agonist and a TLR7/8 agonist; wherein the liposome comprises any one of the TLR4 or TLR7/8 agonists described herein; or wherein the liposome comprises GLA and 3M-052.,True,92718684,Pegylated Liposomes and Methods of Use,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200138715%22.PGNR.&OS=DN/20200138715&RS=DN/20200138715,patent_filed,1588809600.0,3M-052,TLR7,wherein the liposome comprises a TLR4 agonist and a @entityb$ /8 agonist; wherein the liposome comprises any one of the TLR4 or @entityb$ /8 agonists described herein; or wherein the liposome comprises GLA and @entitya$ .,"[-0.3162242  -0.07577391  0.03066655 ... -0.36927962 -0.43312728
  0.5899093 ]",29
digoxin,ace,"Five patients were receiving ACE inhibitors and diuretics, five were receiving digoxin.",True,67967376,Cardiorespiratory system dynamics in chronic heart failure.,https://www.ncbi.nlm.nih.gov/pubmed/12413506,pubmed,1035932400.0,digoxin,ACE,"Five patients were receiving @entityb$ inhibitors and diuretics, five were receiving @entitya$ .","[-0.24586059 -0.72905713 -0.35507622 ...  0.44261464  0.00835333
  0.07835398]",29
3m_052,tlr7,"Hence in some examples, the particles disclosed herein will be used for intratracheal delivery of particles incorporating TLR7/8 agonist (such as 3M-052) and CpG ODN to the lung cancer, to improve survival in subjects having lung cancer.",True,94389559,Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=09919058&OS=09919058&RS=09919058,patent_grant,1521504000.0,3M-052,TLR7,"Hence in some examples, the particles disclosed herein will be used for intratracheal delivery of particles incorporating @entityb$ /8 agonist (such as @entitya$ ) and CpG ODN to the lung cancer, to improve survival in subjects having lung cancer.","[ 0.19205469 -1.5320457  -0.36911803 ... -0.66389936  0.4473238
  0.32581198]",29
loxo_101,trk,"In October 2015, we also announced that the independent committee of the National Cancer Institute-Molecular Analysis for Therapy Choice, or NCI-MATCH, clinical trial chose LOXO-101 as the sole, dedicated treatment arm for patients with TRK gene",True,31262136,"Loxo Oncology, Inc. | 424B5 | 2016-05-11",https://www.sec.gov/Archives/edgar/data/0001581720/0001047469-16-013095.txt,secgov,1462924800.0,LOXO-101,TRK,"In October 2015, we also announced that the independent committee of the National Cancer Institute-Molecular Analysis for Therapy Choice, or NCI-MATCH, clinical trial chose @entitya$ as the sole, dedicated treatment arm for patients with @entityb$ gene","[-0.6455943  -0.3272671   0.24801081 ...  0.32677802  0.5275183
  0.7389935 ]",36
trifluoperazine,tfp,"Trifluoperazine (TFP) has central antiadrenergic, antidopaminergic, and minimal anticholinergic effects.",True,39107128,"METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS, IN PARTICULAR OTC DEFICIENCY",http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200316038%22.PGNR.&OS=DN/20200316038&RS=DN/20200316038,patent_filed,1602115200.0,trifluoperazine,TFP," @entitya$ ( @entityb$ ) has central antiadrenergic, antidopaminergic, and minimal anticholinergic effects.","[-0.73581094  0.22128208  0.22160444 ...  0.09180781 -0.5089744
 -0.13291802]",36
ly3009120,braf,"Because selective BRAF inhibitors paradoxically induce downstream signaling activation, a pan-RAF inhibitor, LY3009120 is a better alternate for KRAS-mutant tumor treatment.",True,11021198,A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.,https://www.ncbi.nlm.nih.gov/pubmed/28576749,pubmed,1496095200.0,LY3009120,BRAF,"Because selective @entityb$ inhibitors paradoxically induce downstream signaling activation, a pan-RAF inhibitor, @entitya$ is a better alternate for KRAS-mutant tumor treatment.","[ 0.57805717  0.31929007  0.6274024  ...  0.22390318 -0.08146671
  0.76209706]",36
loxo_101,trk,"LOXO-101 Phase 1 Update · In the ongoing Phase 1 study, LOXO-101 continues to consistently achieve systemic drug exposures anticipated to inhibit TRK signaling by over 90%.",True,41422011,"Loxo Oncology, Inc. | 8-K | 2015-08-05",https://www.sec.gov/Archives/edgar/data/0001581720/0001104659-15-056091.txt,secgov,1438732800.0,LOXO-101,TRK," @entitya$ Phase 1 Update · In the ongoing Phase 1 study, @entitya$ continues to consistently achieve systemic drug exposures anticipated to inhibit @entityb$ signaling by over 90%.","[ 0.5456811   0.19351117 -0.03770563 ... -0.29176012 -0.49602413
  0.5973395 ]",36
minocycline,angiostatin,"SU11248 (Sunitinib malate), VEGF-Trap, XL184, ZD6474, ATN-161, EMD 121974 (Cilenigtide), Celecoxib, Angiostatin, Endostatin, Regranex, Apligraf, Paclitaxel, tetracyclines, clarithromycin, lasix, captopril, aspirin, Vitamin D3 analogs, retinoids, Imiquomod, Interferon alfa2a, Minocycline, copper peptide containing dressings, Lucentis™, ATG002, Pegaptanib Sodium, Tryptophanyl-tRNA synthetase, squalamine lactate,",True,59384207,Compounds for treating proliferative disorders,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=08497272&OS=08497272&RS=08497272,patent_grant,1375142400.0,Minocycline,Angiostatin,"SU11248 (Sunitinib malate), VEGF-Trap, XL184, ZD6474, ATN-161, EMD 121974 (Cilenigtide), Celecoxib, @entityb$ , Endostatin, Regranex, Apligraf, Paclitaxel, tetracyclines, clarithromycin, lasix, captopril, aspirin, Vitamin D3 analogs, retinoids, Imiquomod, Interferon alfa2a, @entitya$ , copper peptide containing dressings, Lucentis™, ATG002, Pegaptanib Sodium, Tryptophanyl-tRNA synthetase, squalamine lactate,","[ 0.22931132  0.20528841 -0.15262549 ...  0.31773257 -0.13730101
  0.38687187]",36
minocycline,angiostatin,"herbimycin A, PNU145156E, 16K prolactin fragment, Linomide (roquinimex), thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, angiostatin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 or minocycline may be of use.",True,90429609,Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites,http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=09707300&OS=09707300&RS=09707300,patent_grant,1500336000.0,Minocycline,Angiostatin,"herbimycin A, PNU145156E, 16K prolactin fragment, Linomide (roquinimex), thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, @entityb$ , cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 or @entitya$ may be of use.","[ 0.1067503   0.13392855  0.6461936  ...  0.49573085 -0.30909985
  0.34856364]",38
3m_052,tlr7,A striking example of this concerns our recent study of HIV antigens adjuvanted with a TLR7/8 agonist adjuvant called 3M-052 showed the induction of HIV envelope-specific long-lived plasma cells and durable antibody responses in non-human primates [ 107,True,46106815,The immunology of SARS-CoV-2 infections and vaccines,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670910/,pmc,1605571200.0,3M-052,TLR7,A striking example of this concerns our recent study of HIV antigens adjuvanted with a @entityb$ /8 agonist adjuvant called @entitya$ showed the induction of HIV envelope-specific long-lived plasma cells and durable antibody responses in non-human primates [ 107,"[ 0.5443406  -1.1662712  -0.77205735 ... -0.05185247  0.05854058
  0.03551284]",38
trifluoperazine,tfp,"One of the top-ranking candidates, trifluoperazine (TFP), was used to examine the effects on glioma cell proliferation and apoptosis.",True,59285475,Low concentration trifluoperazine promotes proliferation and reduces calcium-dependent apoptosis in glioma cells,https://www.nature.com/articles/s41598-018-19413-y,nature,1516230000.0,trifluoperazine,TFP,"One of the top-ranking candidates, @entitya$ ( @entityb$ ), was used to examine the effects on glioma cell proliferation and apoptosis.","[-0.05222348 -1.1318417  -0.95393544 ... -0.049448    0.3959918
  0.48418728]",38
oxaliplatin,oct2,"All these results suggested that in this study, buflomedil might be effective on abolishing OCT2 mediated oxaliplatin accumulation in DRG, thus alleviating both",True,108808324,SELECTIVE OCT2 INHIBITORS FOR USE IN PREVENTING TOXICITY OF PLATINUM DRUGS,https://data.epo.org/publication-server/rest/v1.2/patents/EP3777851NWA1/document.html,epo,1613516400.0,oxaliplatin,OCT2,"All these results suggested that in this study, buflomedil might be effective on abolishing @entityb$ mediated @entitya$ accumulation in DRG, thus alleviating both","[-0.467582   -0.2990993   0.64365804 ...  0.37714028 -0.4645912
  0.740422  ]",38
tesamorelin,growth hormone releasing factor,"The second poster is entitled ""Efficacy and Long-Term Safety of Tesamorelin, a Growth Hormone-Releasing Factor Analogue, in Sub-Populations of HIV-Infected Patients with Excess Abdominal Fat"" and describes the efficacy and safety of tesamorelin",True,64954534,Theratechnologies Inc.: Tesamorelin Data Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy 50th Annual Meeting,https://www.biospace.com/article/releases/theratechnologies-inc-tesamorelin-data-presented-at-the-b-interscience-b-conference-on-antimicrobial-agents-and-chemotherapy-50th-annual-meeting-/,biospace,1284328800.0,Tesamorelin,Growth Hormone-Releasing Factor,"The second poster is entitled ""Efficacy and Long-Term Safety of @entitya$ , a @entityb$ Analogue, in Sub-Populations of HIV-Infected Patients with Excess Abdominal Fat"" and describes the efficacy and safety of @entitya$ ","[ 0.26011735 -0.6998304  -0.13971187 ...  0.39412224  0.33391684
  0.0240214 ]",38
loxo_101,trk,"In purified enzyme inhibition studies, LOXO-101 demonstrated potent inhibition activity against TRK receptors TRKA, TRKB and TRKC at low concentration levels.",True,43679830,"Loxo Oncology, Inc. | S-1 | 2014-06-30",https://www.sec.gov/Archives/edgar/data/0001581720/0001047469-14-005954.txt,secgov,1404086400.0,LOXO-101,TRK,"In purified enzyme inhibition studies, @entitya$ demonstrated potent inhibition activity against @entityb$ receptors TRKA, TRKB and TRKC at low concentration levels.","[-0.5649027  -0.22101744 -0.17885035 ...  0.7899764  -0.5440974
  0.45417023]",39
minocycline,angiostatin,"Exemplary anti-cancer, anti-angiogenesis compounds included Angiostatin K1 -3, DL-a-difluoromethyl-ornithine, endostatin, fumagillin, genistein, minocycline, staurosporine, and (±)-thalidomide.",True,7192556,FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION,https://data.epo.org/publication-server/rest/v1.2/patents/EP2895513NWB1/document.html,epo,1527026400.0,Minocycline,Angiostatin,"Exemplary anti-cancer, anti-angiogenesis compounds included @entityb$ K1 -3, DL-a-difluoromethyl-ornithine, endostatin, fumagillin, genistein, @entitya$ , staurosporine, and (±)-thalidomide.","[-0.18944152 -0.38756678 -0.1311065  ...  0.19349873  0.15664208
  0.11076894]",39
trifluoperazine,tfp,"possible role of calmodulin in the calcium sensitivity of parathyroid adenylate cyclase (AC), the effect of the calmodulin inhibitor trifluoperazine hydrochloride (TFP) on the calcium sensitivity of forskolin-stimulated AC activity was investigated in membranes prepared from normal porcine parathyroid glands.",True,7009185,The high affinity calcium inhibition of parathyroid adenylate cyclase is not calmodulin dependent.,https://www.ncbi.nlm.nih.gov/pubmed/3087600,pubmed,517788000.0,trifluoperazine,TFP,"possible role of calmodulin in the calcium sensitivity of parathyroid adenylate cyclase (AC), the effect of the calmodulin inhibitor @entitya$ hydrochloride ( @entityb$ ) on the calcium sensitivity of forskolin-stimulated AC activity was investigated in membranes prepared from normal porcine parathyroid glands.","[ 0.33929268  0.04156134 -0.2334802  ...  0.09588154 -0.9252376
  0.978269  ]",39
trifluoperazine,tfp,"conditions with one of the following, CaCl 2 , Ca 2+ -chelator EGTA and the phenothiazines, chlorpromazine (CPZ) and trifluoperazine (TFP), which are known to inhibit efflux pump activity in various pathogens including S. aureus ( Naseem et al., 2008 ;",True,76022057,Evidence of Calcium Signaling and Modulation of the LmrS Multidrug Resistant Efflux Pump Activity by Ca 2 + Ions in S. aureus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642317/,pmc,1603324800.0,trifluoperazine,TFP,"conditions with one of the following, CaCl 2 , Ca 2+ -chelator EGTA and the phenothiazines, chlorpromazine (CPZ) and @entitya$ ( @entityb$ ), which are known to inhibit efflux pump activity in various pathogens including S. aureus ( Naseem et al., 2008 ;","[-0.18704666 -0.13434316  0.75670284 ...  0.45561013 -0.565988
  0.09696241]",39
ly3009120,braf,"Next we tested the effect of the LY3009120 compound in vivo, using two PDXs (M063R.X2 and M048R2.X2) that had acquired the BRAF V600E/DK as resistance mechanism ( Figure 6 A).",True,2639680,BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929150/,pmc,1466035200.0,LY3009120,BRaf,"Next we tested the effect of the @entitya$ compound in vivo, using two PDXs (M063R.X2 and M048R2.X2) that had acquired the @entityb$ V600E/DK as resistance mechanism ( Figure 6 A).","[-0.7253781   0.3143548   0.01967775 ... -0.06319299 -0.22929917
  0.27553523]",39
trifluoperazine,tfp,"Trifluoperazine (TFP), a phenothiazine derivative of an antipsychotic drug, has been known to block the Ca 2+ signal by the inhibition of",True,92375194,A Calcium-Calmodulin Antagonist Blocks Experimental Vibrio vulnificus Cytolysin-Induced Lethality in an Experimental Mouse Model,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517569/,pmc,1096588800.0,trifluoperazine,TFP," @entitya$ ( @entityb$ ), a phenothiazine derivative of an antipsychotic drug, has been known to block the Ca 2+ signal by the inhibition of","[-0.614447   -0.07428895  0.01122252 ...  0.6156955  -0.43850753
  0.2486457 ]",42
loxo_101,trk,"We have demonstrated the promise of this model through the rapid advancement of our TRK inhibitor, LOXO-101, into the clinic.",True,40857668,"Loxo Oncology, Inc. | 424B5 | 2016-05-12",https://www.sec.gov/Archives/edgar/data/0001581720/0001047469-16-013108.txt,secgov,1463011200.0,LOXO-101,TRK,"We have demonstrated the promise of this model through the rapid advancement of our @entityb$ inhibitor, @entitya$ , into the clinic.","[-0.06105851 -0.7824268  -0.49649325 ... -0.3615313   0.01181565
  1.25754   ]",42
3m_052,tlr7,"41 Increased TLR4 expression in nasal tissue could explain why intranasally administered TLR4 ligands such as GLA enhance mucosal IgA. Compared to GLA, the TLR7/8 ligand 3M-052 elicited a stronger Th1-type response in the present work, which is consistent with previous results from our lab where",True,48562580,Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica,https://www.nature.com/articles/s41541-018-0060-x,nature,1528149600.0,3M-052,TLR7,"41 Increased TLR4 expression in nasal tissue could explain why intranasally administered TLR4 ligands such as GLA enhance mucosal IgA. Compared to GLA, the @entityb$ /8 ligand @entitya$ elicited a stronger Th1-type response in the present work, which is consistent with previous results from our lab where","[-0.28119346  0.27950194 -0.26454914 ...  0.11238457 -0.36793163
  0.1895548 ]",42
trifluoperazine,tfp,"Three phenothiazines with similar structure; chlorpromazine (CPZ), triflupromazine (TFPZ), and trifluoperazine (TFP), were compared for the potency of swelling of normal red cells and antisickling effect of red cell from patients with",True,59035322,Comparative studies of phenothiazine derivatives for their effects on swelling of normal and sickle erythrocytes.,https://www.ncbi.nlm.nih.gov/pubmed/7901117,pubmed,743983200.0,trifluoperazine,TFP,"Three phenothiazines with similar structure; chlorpromazine (CPZ), triflupromazine (TFPZ), and @entitya$ ( @entityb$ ), were compared for the potency of swelling of normal red cells and antisickling effect of red cell from patients with","[-0.75438714 -0.96591175 -0.30916494 ...  0.20197654 -0.22644438
  0.12530605]",42
digoxin,ace,"A ""cardiac medicine"" includes but is not limited to natriuretic peptides, ACE inhibitors (ACEIs), beta-adrenergic blocking agents (beta-blockers), vasodilators, diuretics, digitalis preparations ( e.g ., digoxin), dopamine, dobutamine, levosimendan, nesiritide, blood thinners, angiotensin II receptor blockers, calcium channel blockers,",True,69285386,USE OF NATRIURETIC PEPTIDE FOR TREATING HEART FAILURE,https://data.epo.org/publication-server/rest/v1.2/patents/EP1865976NWB1/document.html,epo,1337724000.0,digoxin,ACE,"A ""cardiac medicine"" includes but is not limited to natriuretic peptides, @entityb$ inhibitors (ACEIs), beta-adrenergic blocking agents (beta-blockers), vasodilators, diuretics, digitalis preparations ( e.g ., @entitya$ ), dopamine, dobutamine, levosimendan, nesiritide, blood thinners, angiotensin II receptor blockers, calcium channel blockers,","[ 0.05488956 -0.09918428 -0.46271312 ...  0.51291555 -0.41184893
  0.2242525 ]",42
digoxin,ace,"The method of claim 1 , wherein the selection treatment comprises: calcium channel blockers, ACE inhibitors, beta blockers, digoxin, theophylline, PDE5 inhibitors, prostacyclins, endothelin receptor antagonists, nitric oxide, adenosine or any combination thereof.",True,36843265,METHOD FOR TREATING SECONDARY PULMONARY HYPERTENSION,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200101328%22.PGNR.&OS=DN/20200101328&RS=DN/20200101328,patent_filed,1585785600.0,digoxin,ACE,"The method of claim 1 , wherein the selection treatment comprises: calcium channel blockers, @entityb$ inhibitors, beta blockers, @entitya$ , theophylline, PDE5 inhibitors, prostacyclins, endothelin receptor antagonists, nitric oxide, adenosine or any combination thereof.","[-0.7003215  -0.3225836  -0.43985525 ...  0.26705754 -0.9527683
  0.38941833]",43
digoxin,ace,"The current standard of care for congestive heart failure consists primarily of diuretics, digoxin, angiotensin converting enzyme inhibitors, or ACE- inhibitors and in some cases, a beta blocker.",True,76983175,CARDIOME PHARMA CORP | 20-F | 2002-04-26,https://www.sec.gov/Archives/edgar/data/0001036141/0001062993-02-000161.txt,secgov,1019779200.0,digoxin,ACE,"The current standard of care for congestive heart failure consists primarily of diuretics, @entitya$ , angiotensin converting enzyme inhibitors, or @entityb$ - inhibitors and in some cases, a beta blocker.","[ 0.5022547  -0.5123904  -0.03435212 ...  0.16972834 -0.30897266
 -0.46056518]",43
medi9197,pd_l1,Open in a separate window Fig. 6 MEDI9197 enhances expression of PD1/L1 and increases immune stimulatory and anti-tumor effects of PD-L1 blockade.,True,83908750,Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739946/,pmc,1568160000.0,MEDI9197,PD-L1,Open in a separate window Fig. 6 @entitya$ enhances expression of PD1/L1 and increases immune stimulatory and anti-tumor effects of @entityb$ blockade.,"[-0.921759   -0.5747563  -0.76025444 ...  0.6920522  -0.6473363
  0.7049356 ]",43
loxo_101,trk,"the weekend, boasting of a small but growing number of cases where children and adults with TRK fusion cancer responded to their lead drug, larotrectinib (LOXO-101).",True,63057632,Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval,https://endpts.com/loxo-takes-center-stage-at-asco-with-its-groundbreaking-shot-at-a-biomarker-based-cancer-drug-approval/,endpts,1496472300.0,LOXO-101,TRK,"the weekend, boasting of a small but growing number of cases where children and adults with @entityb$ fusion cancer responded to their lead drug, larotrectinib ( @entitya$ ).","[ 0.2708899  -0.7008978  -0.52709323 ... -0.04272132  0.49260423
  1.0297178 ]",43
conatumumab,dr4,"Several biologics including both recombinant TRAIL (e.g., dulanermin, AMG 951) and agonistic antibodies targeting DR4 or DR5, such as mapatumumab (HGS-ETR1), conatumumab (AMG 655), drozitumab (apomab, PRO95780 ), lexatumumab (HGS-ETR2), tigatuzumab (CS-1008, TRA-8), and others, are in various stages",True,73744628,TNF Superfamily Protein–Protein Interactions: Feasibility of Small-Molecule Modulation,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408546/,pmc,1451606400.0,conatumumab,DR4,"Several biologics including both recombinant TRAIL (e.g., dulanermin, AMG 951) and agonistic antibodies targeting @entityb$ or DR5, such as mapatumumab (HGS-ETR1), @entitya$ (AMG 655), drozitumab (apomab, PRO95780 ), lexatumumab (HGS-ETR2), tigatuzumab (CS-1008, TRA-8), and others, are in various stages","[ 0.23171248 -0.6113881   0.30033025 ...  0.06465878  0.06069411
  1.1027089 ]",43
flurazepam,gaba_a receptor,Point mutation of the γ2 subunit (F77I) greatly reduces the GABA A receptor affinity for zolpidem but not flurazepam in mouse brain ( Cope et al .,True,103587780,Fine mapping of a sedative-hypnotic drug withdrawal locus on mouse chromosome 11.,https://www.ncbi.nlm.nih.gov/pubmed/16436183,pubmed,1141081200.0,Flurazepam,GABA A Receptor,Point mutation of the γ2 subunit (F77I) greatly reduces the @entityb$ affinity for zolpidem but not @entitya$ in mouse brain ( Cope et al .,"[ 0.6317019  -0.6882712  -0.53646064 ...  0.47116616 -0.18606706
  0.45284894]",45
ly3009120,braf,"c-e) Combined treatment with the RAF inhibitor LY3009120 and the MEK inhibitor trametinib c) inhibits signaling after 1 hour of treatment and d) decreases cell viability after 5 days of treatment of M368 cells, the most therapy resistant cell line harboring a BRAF fusion.",True,76019125,Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939448/,pmc,1571097600.0,LY3009120,BRAF,"c-e) Combined treatment with the RAF inhibitor @entitya$ and the MEK inhibitor trametinib c) inhibits signaling after 1 hour of treatment and d) decreases cell viability after 5 days of treatment of M368 cells, the most therapy resistant cell line harboring a @entityb$ fusion.","[ 0.64489746 -0.87106943 -0.00901372 ...  0.6625943  -0.09133799
 -0.23759393]",45
ly3009120,braf,"All BRAF mutants with variable deletions of β3-αC loop have a strong transforming potential, and a robust resistance to Vemurafenib but not LY3009120 that correlates with their dimer affinity Although the oncogenic potential and resistance to RAF inhibitor of BRAF(ΔNVTAP) has been reported recently 31 , 34 , whether all BRAF mutants with in-frame deletions of β3-αC",True,15896951,The Dimer-dependent Catalytic Activity of RAF Family Kinases Is Revealed Through Characterizing Their Oncogenic Mutants,https://www.biorxiv.org/content/10.1101/338293v1,biorxiv,1528063200.0,LY3009120,BRaf,"All @entityb$ mutants with variable deletions of β3-αC loop have a strong transforming potential, and a robust resistance to Vemurafenib but not @entitya$ that correlates with their dimer affinity Although the oncogenic potential and resistance to RAF inhibitor of @entityb$ (ΔNVTAP) has been reported recently 31 , 34 , whether all @entityb$ mutants with in-frame deletions of β3-αC","[ 0.377944   -0.24994949  0.65232456 ...  0.7698673  -0.19348907
  0.1571566 ]",45
flurazepam,gaba_a receptor,"It has also been reported that flurazepam inhibits ERK phosphorylation in the cerebral cortex ( Kalluri and Ticku, 2002 ), which suggests that the memory impairments mediated by GABA A receptor agonists may be associated with the inhibition of",True,17521336,Hippocampal Extracellular Signal-Regulated Kinase Signaling has a Role in Passive Avoidance Memory Retrieval Induced by GABAA Receptor Modulation in Mice,https://www.nature.com/articles/npp2011311,nature,1323817200.0,Flurazepam,GABA A Receptor,"It has also been reported that @entitya$ inhibits ERK phosphorylation in the cerebral cortex ( Kalluri and Ticku, 2002 ), which suggests that the memory impairments mediated by @entityb$ agonists may be associated with the inhibition of","[-4.5529664e-01 -3.3036718e-01 -7.7191475e-03 ... -2.6083548e-04
 -1.1272355e-01  3.1077850e-01]",45
oxaliplatin,oct2,"Together we conclude that epigenetic suppression of OCT2 by miR-489-3p and miR-630 reduces intracellular platinum accumulation and consequently enhances chemoresistance of RCC cells to oxaliplatin, both in vitro and in xenografts.",True,103099805,Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804444/,pmc,1546905600.0,oxaliplatin,OCT2,"Together we conclude that epigenetic suppression of @entityb$ by miR-489-3p and miR-630 reduces intracellular platinum accumulation and consequently enhances chemoresistance of RCC cells to @entitya$ , both in vitro and in xenografts.","[-0.18237841 -0.6133619  -0.18570893 ...  0.04341627  0.24089943
  1.3569907 ]",45
loxo_101,trk, We agree in principle with our colleagues’ endorsement in this journal of the use of the tropomyosin receptor kinase (TRK) inhibitor LOXO-101 (larotrectinib) in children.,True,72268069,"Comment on: “Tumour-agnostic drugs in paediatric cancers”, Chisholm et al., BJC 2020",https://www.nature.com/articles/s41416-020-01103-0,nature,1601503200.0,LOXO-101,TRK, We agree in principle with our colleagues’ endorsement in this journal of the use of the tropomyosin receptor kinase ( @entityb$ ) inhibitor @entitya$ (larotrectinib) in children.,"[-0.15308343 -0.7451423   0.05925067 ...  0.16300812 -0.18444377
  1.0166508 ]",47
trifluoperazine,tfp,"to test the role of NUPR1 on in vitro PC survival through the small molecule inhibition of NUPR1 with trifluoperazine (TFP) [ 50 , 51 ].",True,91250591,Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989470/,pmc,1528156800.0,trifluoperazine,TFP,"to test the role of NUPR1 on in vitro PC survival through the small molecule inhibition of NUPR1 with @entitya$ ( @entityb$ ) [ 50 , 51 ].","[-0.00075069 -0.49043205 -0.33143806 ...  0.6980661  -0.34693226
  0.46867245]",47
ly3009120,braf,"in dog at 10 mg/kg, po administered as solid suspension Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.",True,12627071,"Cmax in dog at 10 mg/kg, po administered as solid suspension",https://pubchem.ncbi.nlm.nih.gov/bioassay/1226934,bioassay,,LY3009120,BRAF,"in dog at 10 mg/kg, po administered as solid suspension Title: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea ( @entitya$ ) as a pan-RAF inhibitor with minimal paradoxical activation and activity against @entityb$ or RAS mutant tumor cells.","[ 0.54799986 -0.11166361  0.37045547 ...  0.07914768 -0.34832326
  0.18375744]",47
tesamorelin,growth hormone releasing factor,Tesamorelin is a growth hormone-releasing factor analogue and is in the final stages of its second,True,51968749,EMD Serono Puts Down $30M for U.S. Rights to Theratechnologies’ Late-Stage Compound,https://www.genengnews.com/news/emd-serono-puts-down-30m-for-u-s-rights-to-theratechnologies-late-stage-compound/,genengnews,1225274614.0,Tesamorelin,Growth Hormone-Releasing Factor, @entitya$ is a @entityb$ analogue and is in the final stages of its second,"[-0.9384947   0.35601676 -0.6846208  ...  0.13788109  0.11175669
  0.5157807 ]",47
loxo_101,trk,"LOXO-101, built specifically to inhibit TRK, is currently being studied in a Phase 1 trial of patients with advanced solid tumors.",True,29392009,"Study shows how TRK-fusion lung cancer escapes LOXO-101, offering new treatment strategies",http://www.eurekalert.org/pub_releases/2016-04/uoca-ssh041216.php,eurekalert,1460844000.0,LOXO-101,TRK," @entitya$ , built specifically to inhibit @entityb$ , is currently being studied in a Phase 1 trial of patients with advanced solid tumors.","[-0.6997341  -0.43974894 -0.6076383  ... -0.14881435  0.14177074
  0.47346896]",47
loxo_101,trk,"In the selection of a clinical candidate, the Sponsor evaluated TRK inhibitors with similar pharmaceutical prope rties and potencies as LOXO-101 at TRKA, TRKB, and TRKC, but varying degrees of CNS penetration, and scored their ataxia based on observations of behavior, gait, and balance in rats.",True,46372659,None,https://www.fda.gov//downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM508676.pdf,fdagov,,LOXO-101,TRK,"In the selection of a clinical candidate, the Sponsor evaluated @entityb$ inhibitors with similar pharmaceutical prope rties and potencies as @entitya$ at TRKA, TRKB, and TRKC, but varying degrees of CNS penetration, and scored their ataxia based on observations of behavior, gait, and balance in rats.","[ 0.38562673 -0.3772842  -0.288246   ...  0.34453347 -0.06561076
  0.51127493]",49
digoxin,ace,"rate, bpm 81±9 82±9 0.72 Medications ACE inhibitor/ARB 28 (90%)/3 (9%) 27 (90%)/4 (13%) 0.96/0.66 Spironolactone 9 (29%) 5 (17%) 0.25 Other diuretics 31 (100%) 30 (100%) 0.99 Statins 4 (13%) 2 (7%) 0.67 Digoxin 2 (6%) 2 (7%) 0.97 Aspirin",True,73744138,Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336834/,pmc,1396915200.0,digoxin,ACE,"rate, bpm 81±9 82±9 0.72 Medications @entityb$ inhibitor/ARB 28 (90%)/3 (9%) 27 (90%)/4 (13%) 0.96/0.66 Spironolactone 9 (29%) 5 (17%) 0.25 Other diuretics 31 (100%) 30 (100%) 0.99 Statins 4 (13%) 2 (7%) 0.67 @entitya$ 2 (6%) 2 (7%) 0.97 Aspirin","[-0.33424205  0.08916204 -0.2007015  ...  0.45300603 -0.10221035
  0.53420717]",49
betahistine,h1,"Examples of the H1 receptor antagonist include ketanserin, thonzylamine, mepyramine, tripelenamine, dimethindene, clemastine, bamipine, isothipendyl, chlorphenoxamine, dimetotiazine, chlorpromazine, hydroxyzine, opipramol, betahistine, cinnarizine, levocabastine, antazoline, diphenylpyraline, carbinoxamine, doxylamine, alimemazine, cyclizine, meclozine, levocetirizine, cyproheptadine, phenindamine,",True,80306112,VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220140220079%22.PGNR.&OS=DN/20140220079&RS=DN/20140220079,patent_filed,1407369600.0,betahistine,H 1,"Examples of the @entityb$ receptor antagonist include ketanserin, thonzylamine, mepyramine, tripelenamine, dimethindene, clemastine, bamipine, isothipendyl, chlorphenoxamine, dimetotiazine, chlorpromazine, hydroxyzine, opipramol, @entitya$ , cinnarizine, levocabastine, antazoline, diphenylpyraline, carbinoxamine, doxylamine, alimemazine, cyclizine, meclozine, levocetirizine, cyproheptadine, phenindamine,","[-0.36104164  0.1429788   0.08253337 ...  0.51013875 -0.71000296
  0.6551986 ]",49
betahistine,h1,"Nasal airway resistance was increased by all 3 agents, with histamine being the most potent effector and with the H2 receptor agonist, impromidine, producing a greater effect than the H1 receptor agonist, betahistine.",True,16172627,The Role of Antihistamines in the Treatment of Vasomotor Rhinitis,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650982/,pmc,1250294400.0,betahistine,H 1,"Nasal airway resistance was increased by all 3 agents, with histamine being the most potent effector and with the H2 receptor agonist, impromidine, producing a greater effect than the @entityb$ receptor agonist, @entitya$ .","[ 0.68061084  0.43216965  0.17550601 ... -0.4565995  -0.82090795
  0.10269521]",49
thyroxine,thyroid hormone receptor,"is a model for the nuclear thyroid hormone receptor, this work would also have major implications bearing on the mechanism of dioxin toxicity and the potential of these compounds to function as potent and persistent thyroxine agonists.",True,19964555,Relative binding affinity against prealbumin in competition binding assay and expressed as relative to L-T4 (100); ND=not determined,https://pubchem.ncbi.nlm.nih.gov/bioassay/161306,bioassay,,thyroxine,thyroid hormone receptor,"is a model for the nuclear @entityb$ , this work would also have major implications bearing on the mechanism of dioxin toxicity and the potential of these compounds to function as potent and persistent @entitya$ agonists.","[ 0.30781814 -0.6459506  -0.47099635 ...  0.1620785  -0.16549245
  0.18796909]",49
trifluoperazine,tfp,The failure of calmodulin antagonists: chlorpromazine (CPZ) and trifluoperazine (TFP) to block the cytotoxic action of PUFAs indicates that calmodulin does not play a role in the proliferation of KB-3-1,True,73179995,Effect of polyunsaturated fatty acids on drug-sensitive and resistant tumor cells in vitro,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180408/,pmc,1315958400.0,trifluoperazine,TFP,The failure of calmodulin antagonists: chlorpromazine (CPZ) and @entitya$ ( @entityb$ ) to block the cytotoxic action of PUFAs indicates that calmodulin does not play a role in the proliferation of KB-3-1,"[ 0.25917634 -0.541426    0.16514282 ...  0.3638205  -0.8490757
  0.07663422]",54
3m_052,tlr7,"SC administration of 3M-052 induced little if any cytokine mRNA expression, but robust IFN-related and TLR7 gene expression in the spleens of treated mice ( FIG.",True,1285037,METHODS AND COMPOSITIONS RELATING TO ADJUVANTS,http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220200108139%22.PGNR.&OS=DN/20200108139&RS=DN/20200108139,patent_filed,1586390400.0,3M-052,TLR7,"SC administration of @entitya$ induced little if any cytokine mRNA expression, but robust IFN-related and @entityb$ gene expression in the spleens of treated mice ( FIG.","[ 0.31551766 -0.45115316  0.04658261 ...  0.72498506 -0.40170226
  0.28665754]",54
digoxin,ace,"Also, the tendency in single drug regimes against the use of ACE inhibitors and a preference for digoxin or diuretics in women and for β‐blockers in men needs attention.",True,40868742,The relevance of comorbidities for heart failure treatment in primary care: A European survey.,https://www.ncbi.nlm.nih.gov/pubmed/16084761,pubmed,1138575600.0,digoxin,ACE,"Also, the tendency in single drug regimes against the use of @entityb$ inhibitors and a preference for @entitya$ or diuretics in women and for β‐blockers in men needs attention.","[ 0.180576   -0.80412555 -0.4151184  ... -0.6403647  -0.51601326
  0.45666438]",54
ly3009120,braf,"similar sensitivities to the RAF dimer inhibitor, LY3009120, which are comparable with that of BRAF(V600E) in A101D melanoma cell line ( Figure 5D&E ).",True,15896951,The Dimer-dependent Catalytic Activity of RAF Family Kinases Is Revealed Through Characterizing Their Oncogenic Mutants,https://www.biorxiv.org/content/10.1101/338293v1,biorxiv,1528063200.0,LY3009120,BRaf,"similar sensitivities to the RAF dimer inhibitor, @entitya$ , which are comparable with that of @entityb$ (V600E) in A101D melanoma cell line ( Figure 5D&E ).","[ 0.2648048  -0.53361166 -0.01625665 ...  0.62852293 -0.0453073
  0.30843326]",54
trifluoperazine,tfp,"CaM antagonists, including trifluoperazine (TFP), W-5, W-7, promethazine and haloperidol, dose-dependently inhibited potassium depolarization-stimulated [3H]HCh-3 binding with IC50s of 20, 40, 70, 30 and 48 (microM), respectively.",True,48823461,Effects of calmodulin antagonists on sodium-dependent high-affinity choline uptake.,https://www.ncbi.nlm.nih.gov/pubmed/2054651,pubmed,667177200.0,trifluoperazine,TFP,"CaM antagonists, including @entitya$ ( @entityb$ ), W-5, W-7, promethazine and haloperidol, dose-dependently inhibited potassium depolarization-stimulated [3H]HCh-3 binding with IC50s of 20, 40, 70, 30 and 48 (microM), respectively.","[ 0.02362507 -0.18027289 -0.26318356 ... -0.0590261  -0.34814712
  0.16889417]",54
trifluoperazine,tfp,"In contrast, TFP (trifluoperazine), an inhibitor of clathrin-mediated endocytosis/recycling /lysosome route for TβRII, neither changes TβRII localization nor reverses PBP-induced TβRII turnover ( Figs",True,83557334,Pentabromophenol suppresses TGF-β signaling by accelerating degradation of type II TGF-β receptors via caveolae-mediated endocytosis,https://www.nature.com/articles/srep43206,nature,1487804400.0,trifluoperazine,TFP,"In contrast, @entityb$ ( @entitya$ ), an inhibitor of clathrin-mediated endocytosis/recycling /lysosome route for TβRII, neither changes TβRII localization nor reverses PBP-induced TβRII turnover ( Figs","[ 0.04815786 -0.55837786  0.3083329  ...  0.70000935 -0.22805174
  0.15030162]",55
ly3009120,braf,Molecular modeling of the BRAF in-frame deletion using protein coordinates from the BRAF/LY3009120 complex (PDB 5C9C).,True,62900787,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,https://www.ncbi.nlm.nih.gov/pubmed/26732095,pubmed,1459288800.0,LY3009120,BRaf,Molecular modeling of the @entityb$ in-frame deletion using protein coordinates from the @entityb$ / @entitya$ complex (PDB 5C9C).,"[-0.4423894  -1.168198   -0.1820771  ...  0.40978462  0.3279217
  0.47457185]",55
3m_052,tlr7,"Open in a separate window Figure 1 Unlike R848, the lipidated, locally acting TLR7/8 agonist 3M-052 demonstrates low serum distribution and little systemic cytokine induction.",True,18437711,TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360187/,pmc,1490227200.0,3M-052,TLR7,"Open in a separate window Figure 1 Unlike R848, the lipidated, locally acting @entityb$ /8 agonist @entitya$ demonstrates low serum distribution and little systemic cytokine induction.","[-0.7313373  -0.21527326 -0.81077296 ... -0.02442072 -0.9984193
  0.34402922]",55
digoxin,ace,"In case of persisting symptoms in patients being treated with diuretics and ACE inhibitors, GPs add spironolactone and digoxin, while cardiologists also use β‐blockers or angiotensin II antagonists as additional therapy (Table 3 ).",True,70829036,Diagnosis and management of heart failure: a questionnaire among general practitioners and cardiologists.,https://www.ncbi.nlm.nih.gov/pubmed/12798833,pubmed,1056924000.0,digoxin,ACE,"In case of persisting symptoms in patients being treated with diuretics and @entityb$ inhibitors, GPs add spironolactone and @entitya$ , while cardiologists also use β‐blockers or angiotensin II antagonists as additional therapy (Table 3 ).",[0.13585839 0.16346388 0.08247498 ... 0.14980562 0.08839237 0.5245077 ],55
oxaliplatin,oct2,"In another example, miconazole exhibited similar potency against OCT2 transport of ASP + and oxaliplatin, but is approximately 70 fold less potent in inhibiting OCT2-mediated metformin transport ( Table 1 ).",True,61949191,SELECTIVE OCT2 INHIBITORS FOR USE IN PREVENTING TOXICITY OF PLATINUM DRUGS,https://data.epo.org/publication-server/rest/v1.2/patents/EP3322414NWB1/document.html,epo,1601416800.0,oxaliplatin,OCT2,"In another example, miconazole exhibited similar potency against @entityb$ transport of ASP + and @entitya$ , but is approximately 70 fold less potent in inhibiting OCT2-mediated metformin transport ( Table 1 ).","[ 0.57459724 -0.42407784 -0.28097832 ...  0.2541766  -0.3579769
  0.4975638 ]",55
